data_5gvo_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 5gvo _Structure_validation_residue.Date_analyzed 2017-03-31 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.287 0 N-CA-C 112.693 -0.163 . . . . 0.0 112.693 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.428 ' O ' ' HB2' ' A' ' 14' ' ' TRP . 1.0 OUTLIER -129.95 127.62 22.76 Favored Pre-proline 0 C--N 1.329 -0.306 0 N-CA-C 110.584 -0.154 . . . . 0.0 110.584 -179.982 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 87.8 Cg_exo -41.62 -30.74 1.05 Allowed 'Trans proline' 0 C--N 1.348 0.544 0 C-N-CA 122.811 2.341 . . . . 0.0 112.96 -179.623 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.5 pt -90.74 150.49 3.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.99 179.827 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 142.86 -104.11 0.35 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.562 -0.827 . . . . 0.0 112.93 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . 0.419 ' N ' ' O ' ' A' ' 15' ' ' TYR . 50.6 t-105 -134.41 -63.73 0.71 Allowed 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 120.589 0.233 . . . . 0.0 111.481 -179.313 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 2.2 t-105 -139.27 177.8 7.65 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-O 121.024 0.44 . . . . 0.0 111.477 -179.158 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.508 ' HA ' ' CD1' ' A' ' 14' ' ' TRP . 6.9 mt -61.15 155.76 3.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.777 -0.647 . . . . 0.0 111.832 -179.581 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . 0.409 ' HG3' ' HB3' ' A' ' 15' ' ' TYR . 4.6 mt-10 -97.72 -175.97 3.33 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.017 179.835 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 11.9 mtm-85 -89.34 -56.55 0.28 Allowed Pre-proline 0 C--N 1.322 -0.601 0 CA-C-N 115.43 -0.805 . . . . 0.0 110.989 179.909 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 62.2 Cg_endo -73.79 -44.79 0.44 Allowed 'Trans proline' 0 C--N 1.346 0.429 0 C-N-CA 122.275 1.983 . . . . 0.0 112.386 179.805 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 5.6 p 177.31 149.88 0.16 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.018 -0.537 . . . . 0.0 111.004 179.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 81.63 -160.87 41.93 Favored Glycine 0 C--N 1.331 0.301 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.845 179.776 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.508 ' CD1' ' HA ' ' A' ' 8' ' ' ILE . 14.4 m0 -119.4 169.99 9.53 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 110.216 -0.29 . . . . 0.0 110.216 179.909 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . 0.419 ' O ' ' N ' ' A' ' 6' ' ' TRP . 19.7 p90 -129.54 170.49 13.68 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-O 120.675 0.274 . . . . 0.0 110.87 179.712 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' PHE . . . . . . . . . . . . . 37.5 m-85 -89.77 155.98 47.57 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.2 -179.793 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -84.78 50.85 3.03 Favored 'Trans proline' 0 N--CA 1.462 -0.36 0 C-N-CA 122.854 2.369 . . . . 0.0 112.593 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 34.7 mt . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.166 -179.928 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.299 0 N-CA-C 112.457 -0.257 . . . . 0.0 112.457 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -128.61 130.06 23.51 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-O 120.469 0.176 . . . . 0.0 110.592 179.887 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_exo -46.36 -26.67 4.19 Favored 'Trans proline' 0 C--N 1.348 0.525 0 C-N-CA 122.544 2.162 . . . . 0.0 112.619 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.3 pt -79.77 149.5 5.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.548 179.662 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . 0.439 ' HA2' ' CE1' ' A' ' 16' ' ' PHE . . . 139.1 -126.41 3.36 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.176 -179.585 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . 0.43 ' HB3' ' CD ' ' A' ' 17' ' ' PRO . 43.4 t-105 -129.66 -44.09 1.23 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.574 0.226 . . . . 0.0 111.59 -179.943 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 1.0 OUTLIER -140.27 177.38 8.04 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.257 0.551 . . . . 0.0 111.689 -179.413 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.511 ' HA ' ' CD1' ' A' ' 14' ' ' TRP . 2.9 mt -67.04 158.84 5.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.265 -0.88 . . . . 0.0 111.844 -179.641 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 2.0 mt-10 -93.91 -175.51 3.74 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.615 -0.721 . . . . 0.0 110.967 179.832 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -89.24 -54.86 0.31 Allowed Pre-proline 0 C--N 1.323 -0.586 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.915 -179.902 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_endo -80.4 -41.23 0.17 Allowed 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.403 2.068 . . . . 0.0 112.33 179.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER 179.97 154.68 0.56 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.057 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 76.94 -157.41 47.02 Favored Glycine 0 CA--C 1.516 0.148 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.653 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.511 ' CD1' ' HA ' ' A' ' 8' ' ' ILE . 11.0 m0 -120.56 -177.35 3.44 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 110.266 -0.272 . . . . 0.0 110.266 179.876 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 8.3 p90 -143.45 168.5 19.68 Favored 'General case' 0 CA--C 1.529 0.137 0 CA-C-O 120.939 0.399 . . . . 0.0 111.656 179.887 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' PHE . . . . . 0.439 ' CE1' ' HA2' ' A' ' 5' ' ' GLY . 0.3 OUTLIER -113.3 96.13 38.22 Favored Pre-proline 0 C--N 1.331 -0.233 0 CA-C-N 115.802 -0.636 . . . . 0.0 110.847 -179.769 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . 0.43 ' CD ' ' HB3' ' A' ' 6' ' ' TRP . 51.8 Cg_endo -69.25 -171.17 0.41 Allowed 'Trans proline' 0 C--N 1.345 0.35 0 C-N-CA 122.571 2.181 . . . . 0.0 112.417 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 29.1 mm . . . . . 0 C--N 1.331 -0.205 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.036 179.94 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.238 0 N-CA-C 112.586 -0.206 . . . . 0.0 112.586 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.471 ' O ' ' HB2' ' A' ' 14' ' ' TRP . 3.8 mp -116.47 112.9 41.01 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-N 116.508 0.154 . . . . 0.0 110.859 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_exo -41.39 -30.16 0.8 Allowed 'Trans proline' 0 C--N 1.35 0.624 0 C-N-CA 122.852 2.368 . . . . 0.0 113.197 -179.821 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.4 pt -92.74 148.07 4.96 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 116.485 -0.325 . . . . 0.0 110.594 179.542 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . 0.42 ' HA2' ' CE1' ' A' ' 16' ' ' PHE . . . 145.71 -105.93 0.36 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.563 -0.827 . . . . 0.0 112.934 -179.792 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 60.9 t-105 -129.83 -63.07 0.93 Allowed 'General case' 0 CA--C 1.53 0.191 0 N-CA-C 111.851 0.315 . . . . 0.0 111.851 -179.26 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.43 ' HB3' ' CZ ' ' A' ' 15' ' ' TYR . 35.3 t-105 -138.42 173.06 12.0 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.741 0.305 . . . . 0.0 111.249 -179.036 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.523 ' HA ' ' CD1' ' A' ' 14' ' ' TRP . 7.4 mt -57.3 154.97 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.406 -179.927 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -89.85 179.26 6.03 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.625 -0.716 . . . . 0.0 110.725 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . 0.427 ' N ' ' CD ' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -89.01 -49.56 0.4 Allowed Pre-proline 0 C--N 1.324 -0.523 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.968 179.883 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.427 ' CD ' ' N ' ' A' ' 10' ' ' ARG . 95.3 Cg_endo -81.38 -38.21 0.25 Allowed 'Trans proline' 0 C--N 1.347 0.5 0 C-N-CA 122.16 1.906 . . . . 0.0 112.267 179.69 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.4 p 172.56 144.81 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.925 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 87.85 -147.55 20.49 Favored Glycine 0 CA--C 1.518 0.26 0 C-N-CA 120.887 -0.673 . . . . 0.0 112.636 179.804 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.523 ' CD1' ' HA ' ' A' ' 8' ' ' ILE . 7.0 m0 -127.69 177.44 6.8 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 110.191 -0.3 . . . . 0.0 110.191 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . 0.43 ' CZ ' ' HB3' ' A' ' 7' ' ' TRP . 6.1 p90 -135.89 174.96 10.03 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-O 120.909 0.385 . . . . 0.0 111.276 179.679 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' PHE . . . . . 0.42 ' CE1' ' HA2' ' A' ' 5' ' ' GLY . 89.6 m-85 -113.07 158.78 36.97 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.647 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -72.15 135.81 25.73 Favored 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.427 2.085 . . . . 0.0 112.296 -179.916 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 3.3 tt . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.158 -179.912 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.27 0 N-CA-C 112.486 -0.246 . . . . 0.0 112.486 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.433 ' CD2' ' N ' ' A' ' 2' ' ' LEU . 0.2 OUTLIER -127.03 136.21 28.52 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 120.519 0.199 . . . . 0.0 110.562 179.748 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_exo -41.9 -28.14 0.71 Allowed 'Trans proline' 0 C--N 1.348 0.545 0 C-N-CA 123.026 2.484 . . . . 0.0 113.511 -179.35 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.3 pt -79.74 148.05 6.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 120.948 0.404 . . . . 0.0 110.868 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . 0.437 ' HA2' ' CD1' ' A' ' 16' ' ' PHE . . . 141.19 -131.02 4.69 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.592 -179.877 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 50.3 t-105 -114.95 -48.55 2.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.561 0.22 . . . . 0.0 111.535 -179.65 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -146.0 178.53 8.13 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.989 0.424 . . . . 0.0 111.033 -179.703 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.574 ' HA ' ' CD1' ' A' ' 14' ' ' TRP . 1.7 mt -58.64 158.44 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.5 -179.716 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . 0.422 ' N ' ' HA ' ' A' ' 14' ' ' TRP . 4.3 tt0 -99.01 176.99 5.38 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.732 -179.873 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . 0.434 ' N ' ' CD ' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -89.46 -49.73 0.39 Allowed Pre-proline 0 C--N 1.326 -0.429 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.148 179.932 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.434 ' CD ' ' N ' ' A' ' 10' ' ' ARG . 91.6 Cg_endo -81.21 -43.79 0.1 OUTLIER 'Trans proline' 0 N--CA 1.46 -0.482 0 C-N-CA 122.334 2.023 . . . . 0.0 112.505 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 17.5 p -177.7 144.1 0.36 Allowed 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.161 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 81.13 -143.83 24.31 Favored Glycine 0 N--CA 1.453 -0.224 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.802 179.681 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.574 ' CD1' ' HA ' ' A' ' 8' ' ' ILE . 11.0 m0 -120.98 174.73 6.44 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 110.406 -0.22 . . . . 0.0 110.406 179.848 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . 0.413 ' CE1' ' HD3' ' A' ' 17' ' ' PRO . 0.2 OUTLIER -134.59 -174.12 3.49 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.91 0.386 . . . . 0.0 111.349 -179.828 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' PHE . . . . . 0.468 ' N ' ' CD2' ' A' ' 16' ' ' PHE . 0.1 OUTLIER -140.46 99.65 7.02 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.8 -179.821 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . 0.413 ' HD3' ' CE1' ' A' ' 15' ' ' TYR . 74.1 Cg_endo -76.02 111.84 3.36 Favored 'Trans proline' 0 C--N 1.345 0.353 0 C-N-CA 122.5 2.134 . . . . 0.0 112.231 -179.968 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 3.2 mp . . . . . 0 C--N 1.33 -0.246 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.115 179.983 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.34 0 N-CA-C 112.603 -0.199 . . . . 0.0 112.603 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.416 ' O ' ' HB2' ' A' ' 14' ' ' TRP . 4.1 mt -131.17 122.58 19.25 Favored Pre-proline 0 C--N 1.329 -0.284 0 N-CA-C 110.579 -0.156 . . . . 0.0 110.579 179.969 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 98.9 Cg_exo -42.46 -30.37 1.52 Allowed 'Trans proline' 0 C--N 1.35 0.607 0 C-N-CA 122.782 2.322 . . . . 0.0 112.949 -179.835 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.9 pt -90.97 150.82 3.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.804 179.633 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . 0.416 ' HA2' ' CD2' ' A' ' 16' ' ' PHE . . . 147.04 -112.23 0.59 Allowed Glycine 0 CA--C 1.518 0.258 0 C-N-CA 120.556 -0.83 . . . . 0.0 112.687 -179.882 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 56.5 t-105 -137.93 -46.05 0.53 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.556 0.217 . . . . 0.0 111.432 -179.639 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.461 ' HB3' ' CZ ' ' A' ' 15' ' ' TYR . 64.4 t-105 -146.69 165.56 29.23 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.0 0.429 . . . . 0.0 111.678 -179.521 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.528 ' HA ' ' CD1' ' A' ' 14' ' ' TRP . 1.7 mt -57.43 158.6 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 115.726 -0.67 . . . . 0.0 111.868 -179.535 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . 0.402 ' HG3' ' HB3' ' A' ' 15' ' ' TYR . 4.5 mt-10 -96.44 -175.67 3.4 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.778 179.724 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.01 -56.46 0.28 Allowed Pre-proline 0 C--N 1.321 -0.663 0 CA-C-N 115.51 -0.768 . . . . 0.0 110.781 179.926 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -74.11 -55.28 0.09 OUTLIER 'Trans proline' 0 C--N 1.346 0.422 0 C-N-CA 122.051 1.834 . . . . 0.0 112.239 179.635 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 70.8 m -168.21 149.89 5.19 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.097 179.926 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 80.59 -162.66 45.57 Favored Glycine 0 C--N 1.331 0.28 0 C-N-CA 120.931 -0.652 . . . . 0.0 113.101 179.45 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.528 ' CD1' ' HA ' ' A' ' 8' ' ' ILE . 16.0 m0 -117.17 176.42 5.15 Favored 'General case' 0 C--N 1.332 -0.194 0 N-CA-C 110.203 -0.295 . . . . 0.0 110.203 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . 0.461 ' CZ ' ' HB3' ' A' ' 7' ' ' TRP . 7.5 p90 -134.71 168.49 18.93 Favored 'General case' 0 N--CA 1.463 0.191 0 CA-C-O 120.883 0.373 . . . . 0.0 111.339 179.793 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' PHE . . . . . 0.416 ' CD2' ' HA2' ' A' ' 5' ' ' GLY . 2.8 m-85 -99.64 152.52 37.83 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.996 -179.862 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -75.72 119.11 5.32 Favored 'Trans proline' 0 C--N 1.345 0.35 0 C-N-CA 122.589 2.193 . . . . 0.0 112.289 179.911 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.2 tt . . . . . 0 C--N 1.329 -0.312 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.147 179.94 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.258 0 N-CA-C 112.653 -0.179 . . . . 0.0 112.653 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.463 ' O ' ' HB2' ' A' ' 14' ' ' TRP . 3.9 mt -125.16 123.39 25.32 Favored Pre-proline 0 C--N 1.331 -0.217 0 O-C-N 122.975 -0.132 . . . . 0.0 110.666 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 97.5 Cg_exo -41.33 -31.75 1.07 Allowed 'Trans proline' 0 C--N 1.349 0.574 0 C-N-CA 122.817 2.345 . . . . 0.0 112.992 -179.781 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.6 pt -92.26 150.6 3.78 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.016 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . 0.422 ' HA2' ' CE1' ' A' ' 16' ' ' PHE . . . 144.36 -106.93 0.42 Allowed Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.616 -0.802 . . . . 0.0 112.874 179.827 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 57.4 t-105 -125.42 -64.55 1.07 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.729 0.3 . . . . 0.0 111.136 -179.603 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.422 ' CE3' HD12 ' A' ' 8' ' ' ILE . 1.1 m95 -144.06 -179.95 6.82 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.096 0.474 . . . . 0.0 111.097 -179.68 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.586 ' HA ' ' CD1' ' A' ' 14' ' ' TRP . 2.5 mp -54.93 158.26 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 115.683 -0.69 . . . . 0.0 111.98 -179.498 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . 0.471 ' HG3' ' HB3' ' A' ' 15' ' ' TYR . 1.9 mt-10 -100.04 179.94 4.34 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.53 -0.759 . . . . 0.0 110.661 179.745 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . 0.412 ' N ' ' CD ' ' A' ' 11' ' ' PRO . 3.3 mmp_? -89.25 -51.44 0.37 Allowed Pre-proline 0 C--N 1.324 -0.534 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.775 179.81 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.412 ' CD ' ' N ' ' A' ' 10' ' ' ARG . 90.8 Cg_endo -80.32 -44.23 0.11 Allowed 'Trans proline' 0 N--CA 1.462 -0.358 0 C-N-CA 122.322 2.015 . . . . 0.0 112.253 179.801 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 16.7 p -178.47 152.13 0.64 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.243 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 75.17 -153.35 44.87 Favored Glycine 0 C--N 1.332 0.325 0 C-N-CA 120.968 -0.634 . . . . 0.0 112.862 179.681 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.586 ' CD1' ' HA ' ' A' ' 8' ' ' ILE . 13.3 m0 -120.37 171.79 8.27 Favored 'General case' 0 C--N 1.332 -0.184 0 N-CA-C 110.292 -0.262 . . . . 0.0 110.292 179.807 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . 0.471 ' HB3' ' HG3' ' A' ' 9' ' ' GLU . 0.0 OUTLIER -129.21 161.96 28.96 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.74 0.305 . . . . 0.0 111.343 179.837 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' PHE . . . . . 0.422 ' CE1' ' HA2' ' A' ' 5' ' ' GLY . 28.4 m-85 -90.05 162.42 35.25 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.813 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -71.15 70.11 2.38 Favored 'Trans proline' 0 C--N 1.346 0.406 0 C-N-CA 122.468 2.112 . . . . 0.0 112.229 -179.881 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 19.8 tt . . . . . 0 C--N 1.328 -0.35 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.07 179.895 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.405 ' N ' ' O ' ' A' ' 14' ' ' TRP . . . . . . . . 0 CA--C 1.518 0.226 0 N-CA-C 112.597 -0.201 . . . . 0.0 112.597 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -136.7 137.62 24.13 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 120.596 0.236 . . . . 0.0 110.599 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_exo -46.17 -28.42 5.5 Favored 'Trans proline' 0 C--N 1.347 0.476 0 C-N-CA 122.672 2.248 . . . . 0.0 112.752 -179.728 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.1 pt -80.07 153.39 4.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.03 179.892 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . 0.433 ' HA2' ' CD2' ' A' ' 16' ' ' PHE . . . 138.16 -123.76 2.76 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.697 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 65.4 t-105 -127.02 -45.65 1.56 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.723 0.297 . . . . 0.0 111.281 -179.708 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 0.4 OUTLIER -146.84 179.94 7.23 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.157 0.504 . . . . 0.0 111.102 -179.52 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.572 ' HA ' ' CD1' ' A' ' 14' ' ' TRP . 1.5 mp -58.23 158.73 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.655 -0.702 . . . . 0.0 111.454 -179.873 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -101.2 175.95 5.41 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.718 -179.884 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . 0.433 ' N ' ' CD ' ' A' ' 11' ' ' PRO . 9.6 ttp180 -89.56 -49.13 0.39 Allowed Pre-proline 0 C--N 1.326 -0.415 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.343 -179.738 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.433 ' CD ' ' N ' ' A' ' 10' ' ' ARG . 90.6 Cg_endo -81.08 -37.48 0.31 Allowed 'Trans proline' 0 C--N 1.347 0.47 0 C-N-CA 122.273 1.982 . . . . 0.0 112.536 -179.803 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER 176.45 149.76 0.13 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.036 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 72.02 -145.59 38.29 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.671 179.666 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.572 ' CD1' ' HA ' ' A' ' 8' ' ' ILE . 12.1 m0 -117.97 179.88 3.96 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.582 0.23 . . . . 0.0 110.49 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . 0.401 ' CD1' ' C ' ' A' ' 15' ' ' TYR . 0.0 OUTLIER -132.32 162.73 30.3 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.854 0.359 . . . . 0.0 111.203 179.987 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' PHE . . . . . 0.433 ' CD2' ' HA2' ' A' ' 5' ' ' GLY . 1.2 m-85 -90.4 146.05 33.76 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.934 -179.881 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 85.3 Cg_endo -78.51 -172.48 1.52 Allowed 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.66 2.24 . . . . 0.0 112.322 179.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 8.9 tp . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.11 179.962 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.295 0 N-CA-C 112.523 -0.231 . . . . 0.0 112.523 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.432 ' CD2' ' N ' ' A' ' 2' ' ' LEU . 0.1 OUTLIER -137.4 125.75 14.59 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 120.457 0.17 . . . . 0.0 110.833 179.966 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 80.2 Cg_exo -44.88 -29.66 3.83 Favored 'Trans proline' 0 C--N 1.348 0.531 0 C-N-CA 122.697 2.265 . . . . 0.0 112.73 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.4 pt -80.63 150.28 4.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.874 179.796 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 141.49 -117.22 1.18 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.498 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 60.1 t-105 -133.29 -44.94 0.84 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.68 0.276 . . . . 0.0 111.419 -179.813 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.426 ' CE2' ' CD1' ' A' ' 8' ' ' ILE . 0.3 OUTLIER -147.2 179.23 7.78 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 121.054 0.454 . . . . 0.0 111.189 -179.485 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.585 ' HA ' ' CD1' ' A' ' 14' ' ' TRP . 2.8 mp -57.69 158.86 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 115.848 -0.614 . . . . 0.0 111.467 -179.878 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . 0.404 ' N ' ' HA ' ' A' ' 14' ' ' TRP . 4.2 tt0 -99.04 179.07 4.74 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.856 -179.882 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . 0.452 ' N ' ' CD ' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -89.33 -47.97 0.41 Allowed Pre-proline 0 C--N 1.326 -0.456 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.456 -179.871 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.452 ' CD ' ' N ' ' A' ' 10' ' ' ARG . 93.2 Cg_endo -82.6 -43.7 0.08 OUTLIER 'Trans proline' 0 C--N 1.347 0.498 0 C-N-CA 122.348 2.032 . . . . 0.0 112.407 -179.808 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.1 p 179.59 142.06 0.13 Allowed 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.848 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 85.49 -143.25 19.98 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.523 179.941 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.585 ' CD1' ' HA ' ' A' ' 8' ' ' ILE . 7.9 m0 -121.87 179.06 4.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.588 0.232 . . . . 0.0 110.672 179.954 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -138.82 -178.22 5.22 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-O 120.878 0.37 . . . . 0.0 110.788 179.919 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' PHE . . . . . . . . . . . . . 3.7 m-85 -104.97 160.87 24.5 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.092 -179.838 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -75.83 -165.28 0.29 Allowed 'Trans proline' 0 C--N 1.345 0.357 0 C-N-CA 122.78 2.32 . . . . 0.0 112.273 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.5 mp . . . . . 0 C--N 1.33 -0.247 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.95 179.986 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.401 ' N ' ' O ' ' A' ' 14' ' ' TRP . . . . . . . . 0 N--CA 1.45 -0.371 0 N-CA-C 112.524 -0.23 . . . . 0.0 112.524 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 15.1 mt -145.68 137.92 13.47 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 120.481 0.181 . . . . 0.0 110.87 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_exo -48.35 -27.4 9.87 Favored 'Trans proline' 0 C--N 1.346 0.442 0 C-N-CA 122.484 2.122 . . . . 0.0 112.492 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.8 pt -86.86 152.56 3.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.907 179.856 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 143.66 -116.57 0.99 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.421 -179.86 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 61.9 t-105 -133.82 -47.16 0.8 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.709 0.29 . . . . 0.0 111.039 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 9.6 t-105 -149.93 176.39 10.8 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.914 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.538 ' HA ' ' CD1' ' A' ' 14' ' ' TRP . 4.1 mm -48.14 159.22 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.638 -179.901 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . 0.404 ' N ' ' HA ' ' A' ' 14' ' ' TRP . 3.0 tt0 -105.33 178.17 4.64 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.707 179.909 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . 0.416 ' N ' ' CD ' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -89.41 -51.24 0.37 Allowed Pre-proline 0 C--N 1.326 -0.438 0 CA-C-N 115.975 -0.557 . . . . 0.0 111.187 -179.779 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.416 ' CD ' ' N ' ' A' ' 10' ' ' ARG . 72.0 Cg_endo -81.33 -48.5 0.06 OUTLIER 'Trans proline' 0 C--N 1.346 0.44 0 C-N-CA 122.293 1.995 . . . . 0.0 112.439 -179.892 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 67.6 m -166.57 157.08 12.19 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.957 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 59.51 -149.82 39.16 Favored Glycine 0 N--CA 1.452 -0.248 0 C-N-CA 120.862 -0.685 . . . . 0.0 112.648 179.764 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.538 ' CD1' ' HA ' ' A' ' 8' ' ' ILE . 30.2 m0 -109.92 179.4 4.12 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.591 0.234 . . . . 0.0 110.601 -179.861 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . 0.408 ' CD2' ' O ' ' A' ' 16' ' ' PHE . 1.1 p90 -131.98 167.18 20.11 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.828 0.347 . . . . 0.0 110.984 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' PHE . . . . . 0.408 ' O ' ' CD2' ' A' ' 15' ' ' TYR . 10.5 m-85 -102.78 163.08 18.3 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.913 -179.963 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo -67.48 88.69 0.34 Allowed 'Trans proline' 0 C--N 1.346 0.409 0 C-N-CA 122.638 2.225 . . . . 0.0 112.327 179.893 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.9 mm . . . . . 0 C--N 1.327 -0.38 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.191 179.842 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.4 0 N-CA-C 112.478 -0.249 . . . . 0.0 112.478 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.3 mt -139.18 144.88 42.42 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 120.631 0.253 . . . . 0.0 110.831 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_exo -50.34 -24.93 12.71 Favored 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.575 2.184 . . . . 0.0 112.447 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.9 pt -79.8 154.39 4.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.055 179.855 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 134.88 -121.65 2.67 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.455 -179.863 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 36.0 t-105 -134.68 -44.19 0.75 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.685 0.278 . . . . 0.0 111.351 -179.84 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 0.5 OUTLIER -147.4 -179.32 6.77 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 121.095 0.474 . . . . 0.0 111.09 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.594 ' HA ' ' CD1' ' A' ' 14' ' ' TRP . 13.5 mt -53.75 158.53 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 115.688 -0.687 . . . . 0.0 111.718 -179.69 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 3.6 tt0 -105.52 177.49 4.84 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.789 -0.642 . . . . 0.0 110.866 -179.703 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . 0.448 ' N ' ' CD ' ' A' ' 11' ' ' PRO . 12.3 tpp180 -89.61 -46.59 0.41 Allowed Pre-proline 0 C--N 1.327 -0.389 0 CA-C-N 115.797 -0.638 . . . . 0.0 111.932 -179.574 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.448 ' CD ' ' N ' ' A' ' 10' ' ' ARG . 71.8 Cg_endo -80.69 -48.09 0.07 OUTLIER 'Trans proline' 0 C--N 1.349 0.582 0 C-N-CA 122.209 1.939 . . . . 0.0 112.804 -179.475 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 4.3 p -179.3 129.04 0.1 Allowed 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.93 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 96.52 -141.33 15.54 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.455 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.594 ' CD1' ' HA ' ' A' ' 8' ' ' ILE . 10.0 m0 -120.48 174.78 6.34 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.736 0.303 . . . . 0.0 110.778 179.92 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . 0.401 ' CE1' ' O ' ' A' ' 16' ' ' PHE . 0.1 OUTLIER -132.38 177.73 7.37 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.383 -0.372 . . . . 0.0 110.596 179.951 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' PHE . . . . . 0.401 ' O ' ' CE1' ' A' ' 15' ' ' TYR . 26.1 m-85 -89.77 160.9 40.25 Favored Pre-proline 0 C--N 1.328 -0.365 0 CA-C-N 116.418 -0.355 . . . . 0.0 111.025 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 68.2 Cg_endo -74.49 76.24 3.23 Favored 'Trans proline' 0 C--N 1.343 0.286 0 C-N-CA 122.722 2.281 . . . . 0.0 112.238 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 7.5 tp . . . . . 0 C--N 1.33 -0.281 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.076 -179.99 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.388 0 N-CA-C 112.793 -0.123 . . . . 0.0 112.793 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 15.0 mt -140.6 142.63 29.55 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-O 120.507 0.194 . . . . 0.0 110.858 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 81.2 Cg_exo -48.02 -27.94 9.71 Favored 'Trans proline' 0 C--N 1.346 0.404 0 C-N-CA 122.655 2.237 . . . . 0.0 112.53 -179.834 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 8.2 pt -83.39 160.23 3.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.8 179.804 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 133.39 -121.62 2.88 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.653 -0.785 . . . . 0.0 112.687 -179.911 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 70.9 t-105 -128.41 -49.45 1.29 Allowed 'General case' 0 C--N 1.331 -0.203 0 N-CA-C 111.599 0.222 . . . . 0.0 111.599 -179.697 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.423 ' CD1' HD11 ' A' ' 8' ' ' ILE . 1.6 t-105 -148.87 175.1 11.55 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.898 0.38 . . . . 0.0 111.199 -179.447 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.575 ' HA ' ' CD1' ' A' ' 14' ' ' TRP . 2.2 mp -48.77 155.46 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.622 -179.738 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . 0.449 ' HG3' ' HB3' ' A' ' 15' ' ' TYR . 2.8 tt0 -100.69 177.93 4.85 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.896 -0.593 . . . . 0.0 111.136 -179.681 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . 0.431 ' N ' ' CD ' ' A' ' 11' ' ' PRO . 1.9 tpt180 -89.43 -50.03 0.38 Allowed Pre-proline 0 C--N 1.326 -0.423 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.212 179.961 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.431 ' CD ' ' N ' ' A' ' 10' ' ' ARG . 89.9 Cg_endo -82.89 -39.67 0.13 Allowed 'Trans proline' 0 C--N 1.348 0.512 0 C-N-CA 122.491 2.127 . . . . 0.0 112.544 -179.804 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 17.9 p -177.52 157.77 1.31 Allowed 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.056 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 59.82 -148.5 42.23 Favored Glycine 0 N--CA 1.453 -0.215 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.517 179.909 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.575 ' CD1' ' HA ' ' A' ' 8' ' ' ILE . 30.5 m0 -115.54 174.96 5.74 Favored 'General case' 0 C--N 1.332 -0.186 0 C-N-CA 122.183 0.193 . . . . 0.0 110.513 179.96 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . 0.496 ' CD2' ' O ' ' A' ' 8' ' ' ILE . 3.3 p90 -122.08 166.6 14.28 Favored 'General case' 0 N--CA 1.462 0.172 0 CA-C-O 120.794 0.33 . . . . 0.0 110.688 179.151 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' PHE . . . . . . . . . . . . . 1.8 m-85 -91.19 148.02 36.88 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.899 179.843 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -72.65 71.42 3.25 Favored 'Trans proline' 0 C--N 1.345 0.363 0 C-N-CA 122.563 2.175 . . . . 0.0 112.487 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 40.9 mt . . . . . 0 C--N 1.328 -0.353 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.049 -179.903 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.333 0 N-CA-C 112.425 -0.27 . . . . 0.0 112.425 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.406 ' O ' ' HB2' ' A' ' 14' ' ' TRP . 0.3 OUTLIER -128.48 145.35 55.58 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 120.522 0.201 . . . . 0.0 110.614 179.929 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 82.0 Cg_exo -44.37 -28.37 2.5 Favored 'Trans proline' 0 C--N 1.347 0.467 0 C-N-CA 122.705 2.27 . . . . 0.0 112.755 -179.848 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.4 pt -79.84 151.85 4.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.765 179.725 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . 0.404 ' HA2' ' CZ ' ' A' ' 16' ' ' PHE . . . 133.81 -120.5 2.53 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.578 -179.948 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 24.2 t-105 -121.74 -64.61 1.2 Allowed 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 120.642 0.258 . . . . 0.0 111.31 -179.75 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.422 ' CE2' HD13 ' A' ' 8' ' ' ILE . 0.0 OUTLIER -140.7 177.19 8.2 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.846 0.355 . . . . 0.0 111.154 -179.582 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.595 ' HA ' ' CD1' ' A' ' 14' ' ' TRP . 2.5 mp -46.19 155.53 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.435 -179.77 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 3.3 tt0 -102.81 179.82 4.17 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.091 -179.534 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . 0.439 ' N ' ' CD ' ' A' ' 11' ' ' PRO . 7.7 mtt-85 -89.36 -48.41 0.4 Allowed Pre-proline 0 C--N 1.325 -0.493 0 CA-C-N 115.581 -0.736 . . . . 0.0 111.149 179.908 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.439 ' CD ' ' N ' ' A' ' 10' ' ' ARG . 93.1 Cg_endo -82.25 -40.93 0.13 Allowed 'Trans proline' 0 C--N 1.346 0.446 0 C-N-CA 122.352 2.035 . . . . 0.0 112.424 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.2 p 175.87 144.54 0.07 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.992 179.912 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 81.11 -142.89 23.57 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.708 179.812 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.595 ' CD1' ' HA ' ' A' ' 8' ' ' ILE . 13.4 m0 -123.07 168.7 12.03 Favored 'General case' 0 CA--C 1.53 0.207 0 N-CA-C 110.276 -0.268 . . . . 0.0 110.276 179.91 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . 0.442 ' CD2' ' O ' ' A' ' 8' ' ' ILE . 4.1 p90 -114.95 177.58 4.6 Favored 'General case' 0 N--CA 1.463 0.218 0 CA-C-O 120.845 0.355 . . . . 0.0 110.885 179.442 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' PHE . . . . . 0.404 ' CZ ' ' HA2' ' A' ' 5' ' ' GLY . 5.4 m-85 -119.83 152.78 54.25 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.743 179.901 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -75.81 58.95 5.57 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.573 2.182 . . . . 0.0 112.353 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 5.6 tp . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.054 -179.915 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.318 0 N-CA-C 112.417 -0.273 . . . . 0.0 112.417 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.405 ' HA ' ' HD3' ' A' ' 3' ' ' PRO . 0.0 OUTLIER -130.71 142.26 44.9 Favored Pre-proline 0 C--N 1.329 -0.298 0 N-CA-C 110.521 -0.177 . . . . 0.0 110.521 179.877 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.405 ' HD3' ' HA ' ' A' ' 2' ' ' LEU . 16.6 Cg_exo -67.42 59.58 0.72 Allowed 'Trans proline' 0 C--N 1.347 0.484 0 C-N-CA 122.664 2.243 . . . . 0.0 112.517 -179.858 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 12.2 pt -160.09 167.28 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.727 179.876 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . 0.415 ' HA2' ' CD1' ' A' ' 16' ' ' PHE . . . 116.64 -99.22 0.84 Allowed Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.588 -0.815 . . . . 0.0 112.591 179.897 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 48.9 t-105 -149.39 -39.31 0.15 Allowed 'General case' 0 C--N 1.33 -0.246 0 N-CA-C 111.779 0.289 . . . . 0.0 111.779 -179.714 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 1.4 t-105 -145.13 178.81 7.79 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 121.184 0.516 . . . . 0.0 111.422 -179.437 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.563 ' HA ' ' CD1' ' A' ' 14' ' ' TRP . 1.5 mt -62.49 158.5 3.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.512 -0.767 . . . . 0.0 111.36 -179.829 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . 0.407 ' N ' ' HA ' ' A' ' 14' ' ' TRP . 4.3 tt0 -95.9 176.46 6.11 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.916 -0.583 . . . . 0.0 110.849 179.887 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . 0.473 ' N ' ' CD ' ' A' ' 11' ' ' PRO . 10.3 ttt180 -89.43 -45.47 0.42 Allowed Pre-proline 0 C--N 1.326 -0.416 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.567 -179.86 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.473 ' CD ' ' N ' ' A' ' 10' ' ' ARG . 92.1 Cg_endo -82.5 -44.13 0.08 OUTLIER 'Trans proline' 0 C--N 1.349 0.572 0 C-N-CA 122.129 1.886 . . . . 0.0 112.388 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 21.4 p 177.17 133.37 0.06 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.853 179.894 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 97.13 -142.2 16.04 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.675 179.868 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.563 ' CD1' ' HA ' ' A' ' 8' ' ' ILE . 5.8 m0 -125.74 -177.71 4.01 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.608 0.242 . . . . 0.0 110.644 -179.965 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -147.96 170.96 16.58 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 120.807 0.337 . . . . 0.0 111.106 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' PHE . . . . . 0.415 ' CD1' ' HA2' ' A' ' 5' ' ' GLY . 29.3 m-85 -96.64 161.63 25.99 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.877 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -73.25 154.22 51.44 Favored 'Trans proline' 0 C--N 1.344 0.317 0 C-N-CA 122.536 2.157 . . . . 0.0 112.282 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 29.8 mm . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.13 179.968 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.418 0 N-CA-C 112.658 -0.177 . . . . 0.0 112.658 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.412 ' O ' ' HB2' ' A' ' 14' ' ' TRP . 0.5 OUTLIER -125.43 130.65 24.05 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 120.397 0.141 . . . . 0.0 110.648 179.878 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 99.6 Cg_exo -42.03 -31.24 1.48 Allowed 'Trans proline' 0 C--N 1.348 0.532 0 C-N-CA 122.785 2.323 . . . . 0.0 112.854 -179.826 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.5 pt -83.29 149.64 4.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.86 179.754 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 141.72 -111.16 0.68 Allowed Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.544 -0.836 . . . . 0.0 112.581 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 73.5 t-105 -133.4 -59.32 0.87 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.507 0.194 . . . . 0.0 111.512 -179.617 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 0.8 OUTLIER -135.62 179.05 6.57 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 121.051 0.453 . . . . 0.0 111.489 -179.359 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.524 ' HA ' ' CD1' ' A' ' 14' ' ' TRP . 6.0 mt -65.64 153.64 8.17 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 115.753 -0.658 . . . . 0.0 111.332 -179.848 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -93.44 179.97 5.23 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.692 -0.685 . . . . 0.0 111.115 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . 0.407 ' N ' ' HD2' ' A' ' 11' ' ' PRO . 3.3 ttt180 -89.44 -52.29 0.35 Allowed Pre-proline 0 C--N 1.325 -0.463 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.2 -179.786 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.407 ' HD2' ' N ' ' A' ' 10' ' ' ARG . 72.8 Cg_endo -78.04 -41.27 0.31 Allowed 'Trans proline' 0 C--N 1.347 0.46 0 C-N-CA 122.339 2.026 . . . . 0.0 112.465 -179.905 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER 175.69 145.73 0.08 Allowed 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.1 179.872 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 83.89 -152.26 28.4 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.857 179.803 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.524 ' CD1' ' HA ' ' A' ' 8' ' ' ILE . 9.1 m0 -123.53 173.53 7.98 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 110.407 -0.22 . . . . 0.0 110.407 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . 0.436 ' CD2' ' O ' ' A' ' 8' ' ' ILE . 6.6 p90 -125.71 164.71 20.05 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.698 0.285 . . . . 0.0 110.698 179.691 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' PHE . . . . . . . . . . . . . 11.4 m-85 -90.05 151.55 45.16 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.853 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -77.74 160.71 31.03 Favored 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.691 2.261 . . . . 0.0 112.607 -179.898 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.411 ' N ' ' CD1' ' A' ' 18' ' ' ILE . 2.7 mp . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.743 179.772 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.434 ' N ' ' O ' ' A' ' 14' ' ' TRP . . . . . . . . 0 N--CA 1.452 -0.249 0 N-CA-C 112.592 -0.203 . . . . 0.0 112.592 . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -134.58 130.85 20.04 Favored Pre-proline 0 C--N 1.331 -0.211 0 CA-C-O 120.458 0.17 . . . . 0.0 110.572 -179.93 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 92.0 Cg_exo -42.45 -29.19 1.18 Allowed 'Trans proline' 0 C--N 1.347 0.496 0 C-N-CA 122.905 2.403 . . . . 0.0 113.209 -179.555 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.1 pt -79.85 150.49 4.96 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 116.531 -0.304 . . . . 0.0 110.772 179.843 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . 0.444 ' HA2' ' CE2' ' A' ' 16' ' ' PHE . . . 141.01 -132.47 5.39 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.538 -179.713 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 35.0 t-105 -119.29 -39.66 2.88 Favored 'General case' 0 C--N 1.332 -0.194 0 N-CA-C 111.673 0.249 . . . . 0.0 111.673 -179.633 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 2.4 t-105 -150.15 175.54 11.65 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.956 0.408 . . . . 0.0 111.101 -179.611 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.55 ' HA ' ' CD1' ' A' ' 14' ' ' TRP . 2.7 mp -58.06 159.12 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.389 -179.865 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . 0.445 ' N ' ' HA ' ' A' ' 14' ' ' TRP . 3.9 tt0 -101.34 176.38 5.26 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.728 -179.892 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . 0.436 ' N ' ' CD ' ' A' ' 11' ' ' PRO . 2.3 tpt180 -89.59 -48.43 0.4 Allowed Pre-proline 0 C--N 1.327 -0.392 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.36 -179.782 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.436 ' CD ' ' N ' ' A' ' 10' ' ' ARG . 72.7 Cg_endo -80.15 -51.2 0.05 OUTLIER 'Trans proline' 0 C--N 1.347 0.5 0 C-N-CA 122.154 1.903 . . . . 0.0 112.523 -179.862 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -169.75 140.79 2.18 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.048 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 80.49 -145.85 26.84 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.931 -0.652 . . . . 0.0 112.724 179.718 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.55 ' CD1' ' HA ' ' A' ' 8' ' ' ILE . 15.2 m0 -115.6 -179.26 3.59 Favored 'General case' 0 C--N 1.331 -0.231 0 N-CA-C 110.421 -0.214 . . . . 0.0 110.421 -179.97 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . 0.408 ' CD2' ' C ' ' A' ' 15' ' ' TYR . 0.1 OUTLIER -129.81 173.96 10.17 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.986 0.422 . . . . 0.0 111.531 -179.679 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' PHE . . . . . 0.444 ' CE2' ' HA2' ' A' ' 5' ' ' GLY . 0.8 OUTLIER -122.41 137.17 27.3 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.843 -179.971 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_endo -80.34 150.65 19.88 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.579 2.186 . . . . 0.0 112.339 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 26.1 mm . . . . . 0 C--N 1.33 -0.248 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.026 179.93 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.287 0 N-CA-C 112.693 -0.163 . . . . 0.0 112.693 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.449 ' O ' ' HB2' ' A' ' 14' ' ' TRP . 1.0 OUTLIER -129.95 127.62 22.76 Favored Pre-proline 0 C--N 1.329 -0.306 0 N-CA-C 110.584 -0.154 . . . . 0.0 110.584 -179.982 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 87.8 Cg_exo -41.62 -30.74 1.05 Allowed 'Trans proline' 0 C--N 1.348 0.544 0 C-N-CA 122.811 2.341 . . . . 0.0 112.96 -179.623 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.5 pt -90.74 150.49 3.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.99 179.827 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 142.86 -104.11 0.35 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.562 -0.827 . . . . 0.0 112.93 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' TRP . . . . . 0.419 ' N ' ' O ' ' A' ' 15' ' ' TYR . 50.6 t-105 -134.41 -63.73 0.71 Allowed 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 120.589 0.233 . . . . 0.0 111.481 -179.313 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 2.2 t-105 -139.27 177.8 7.65 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-O 121.024 0.44 . . . . 0.0 111.477 -179.158 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.524 ' HA ' ' CD1' ' A' ' 14' ' ' TRP . 6.9 mt -61.15 155.76 3.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.777 -0.647 . . . . 0.0 111.832 -179.581 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.437 ' HG3' ' HB3' ' A' ' 15' ' ' TYR . 4.6 mt-10 -97.72 -175.97 3.33 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.017 179.835 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.436 ' H ' ' HD2' ' A' ' 11' ' ' PRO . 11.9 mtm-85 -89.34 -56.55 0.28 Allowed Pre-proline 0 C--N 1.322 -0.601 0 CA-C-N 115.43 -0.805 . . . . 0.0 110.989 179.909 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.436 ' HD2' ' H ' ' A' ' 10' ' ' ARG . 62.2 Cg_endo -73.79 -44.79 0.44 Allowed 'Trans proline' 0 C--N 1.346 0.429 0 C-N-CA 122.275 1.983 . . . . 0.0 112.386 179.805 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 5.6 p 177.31 149.88 0.16 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.018 -0.537 . . . . 0.0 111.004 179.915 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 81.63 -160.87 41.93 Favored Glycine 0 C--N 1.331 0.301 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.845 179.776 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.524 ' CD1' ' HA ' ' A' ' 8' ' ' ILE . 14.4 m0 -119.4 169.99 9.53 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 110.216 -0.29 . . . . 0.0 110.216 179.909 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' TYR . . . . . 0.437 ' HB3' ' HG3' ' A' ' 9' ' ' GLU . 19.7 p90 -129.54 170.49 13.68 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-O 120.675 0.274 . . . . 0.0 110.87 179.712 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' PHE . . . . . . . . . . . . . 37.5 m-85 -89.77 155.98 47.57 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.2 -179.793 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -84.78 50.85 3.03 Favored 'Trans proline' 0 N--CA 1.462 -0.36 0 C-N-CA 122.854 2.369 . . . . 0.0 112.593 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 34.7 mt . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.166 -179.928 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.299 0 N-CA-C 112.457 -0.257 . . . . 0.0 112.457 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.898 HD12 HG13 ' A' ' 4' ' ' ILE . 0.1 OUTLIER -128.61 130.06 23.51 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-O 120.469 0.176 . . . . 0.0 110.592 179.887 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_exo -46.36 -26.67 4.19 Favored 'Trans proline' 0 C--N 1.348 0.525 0 C-N-CA 122.544 2.162 . . . . 0.0 112.619 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.898 HG13 HD12 ' A' ' 2' ' ' LEU . 3.3 pt -79.77 149.5 5.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.548 179.662 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.447 ' HA2' ' CD1' ' A' ' 16' ' ' PHE . . . 139.1 -126.41 3.36 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.176 -179.585 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' TRP . . . . . 0.459 ' HB3' ' CD ' ' A' ' 17' ' ' PRO . 43.4 t-105 -129.66 -44.09 1.23 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.574 0.226 . . . . 0.0 111.59 -179.943 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 1.0 OUTLIER -140.27 177.38 8.04 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.257 0.551 . . . . 0.0 111.689 -179.413 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.518 ' HA ' ' CD1' ' A' ' 14' ' ' TRP . 2.9 mt -67.04 158.84 5.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.265 -0.88 . . . . 0.0 111.844 -179.641 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.495 ' N ' HG22 ' A' ' 8' ' ' ILE . 2.0 mt-10 -93.91 -175.51 3.74 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.615 -0.721 . . . . 0.0 110.967 179.832 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -89.24 -54.86 0.31 Allowed Pre-proline 0 C--N 1.323 -0.586 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.915 -179.902 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_endo -80.4 -41.23 0.17 Allowed 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.403 2.068 . . . . 0.0 112.33 179.883 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER 179.97 154.68 0.56 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.057 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 76.94 -157.41 47.02 Favored Glycine 0 CA--C 1.516 0.148 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.653 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.518 ' CD1' ' HA ' ' A' ' 8' ' ' ILE . 11.0 m0 -120.56 -177.35 3.44 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 110.266 -0.272 . . . . 0.0 110.266 179.876 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' TYR . . . . . 0.437 ' HB3' ' HG3' ' A' ' 9' ' ' GLU . 8.3 p90 -143.45 168.5 19.68 Favored 'General case' 0 CA--C 1.529 0.137 0 CA-C-O 120.939 0.399 . . . . 0.0 111.656 179.887 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' PHE . . . . . 0.638 ' HE1' HD12 ' A' ' 4' ' ' ILE . 0.3 OUTLIER -113.3 96.13 38.22 Favored Pre-proline 0 C--N 1.331 -0.233 0 CA-C-N 115.802 -0.636 . . . . 0.0 110.847 -179.769 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.564 ' O ' HD13 ' A' ' 18' ' ' ILE . 51.8 Cg_endo -69.25 -171.17 0.41 Allowed 'Trans proline' 0 C--N 1.345 0.35 0 C-N-CA 122.571 2.181 . . . . 0.0 112.417 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.564 HD13 ' O ' ' A' ' 17' ' ' PRO . 29.1 mm . . . . . 0 C--N 1.331 -0.205 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.036 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.238 0 N-CA-C 112.586 -0.206 . . . . 0.0 112.586 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.502 ' O ' ' HB2' ' A' ' 14' ' ' TRP . 3.8 mp -116.47 112.9 41.01 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-N 116.508 0.154 . . . . 0.0 110.859 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_exo -41.39 -30.16 0.8 Allowed 'Trans proline' 0 C--N 1.35 0.624 0 C-N-CA 122.852 2.368 . . . . 0.0 113.197 -179.821 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.4 pt -92.74 148.07 4.96 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 116.485 -0.325 . . . . 0.0 110.594 179.542 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.436 ' HA2' ' CE1' ' A' ' 16' ' ' PHE . . . 145.71 -105.93 0.36 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.563 -0.827 . . . . 0.0 112.934 -179.792 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 60.9 t-105 -129.83 -63.07 0.93 Allowed 'General case' 0 CA--C 1.53 0.191 0 N-CA-C 111.851 0.315 . . . . 0.0 111.851 -179.26 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.451 ' HB3' ' CZ ' ' A' ' 15' ' ' TYR . 35.3 t-105 -138.42 173.06 12.0 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.741 0.305 . . . . 0.0 111.249 -179.036 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.543 ' HA ' ' CD1' ' A' ' 14' ' ' TRP . 7.4 mt -57.3 154.97 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.406 -179.927 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.411 ' N ' HG22 ' A' ' 8' ' ' ILE . 2.2 tt0 -89.85 179.26 6.03 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.625 -0.716 . . . . 0.0 110.725 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.427 ' N ' ' CD ' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -89.01 -49.56 0.4 Allowed Pre-proline 0 C--N 1.324 -0.523 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.968 179.883 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.427 ' CD ' ' N ' ' A' ' 10' ' ' ARG . 95.3 Cg_endo -81.38 -38.21 0.25 Allowed 'Trans proline' 0 C--N 1.347 0.5 0 C-N-CA 122.16 1.906 . . . . 0.0 112.267 179.69 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.4 p 172.56 144.81 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.925 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 87.85 -147.55 20.49 Favored Glycine 0 CA--C 1.518 0.26 0 C-N-CA 120.887 -0.673 . . . . 0.0 112.636 179.804 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.543 ' CD1' ' HA ' ' A' ' 8' ' ' ILE . 7.0 m0 -127.69 177.44 6.8 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 110.191 -0.3 . . . . 0.0 110.191 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' TYR . . . . . 0.451 ' CZ ' ' HB3' ' A' ' 7' ' ' TRP . 6.1 p90 -135.89 174.96 10.03 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-O 120.909 0.385 . . . . 0.0 111.276 179.679 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' PHE . . . . . 0.436 ' CE1' ' HA2' ' A' ' 5' ' ' GLY . 89.6 m-85 -113.07 158.78 36.97 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.647 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -72.15 135.81 25.73 Favored 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.427 2.085 . . . . 0.0 112.296 -179.916 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 3.3 tt . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.158 -179.912 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.27 0 N-CA-C 112.486 -0.246 . . . . 0.0 112.486 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.885 HD12 ' CG1' ' A' ' 4' ' ' ILE . 0.2 OUTLIER -127.03 136.21 28.52 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 120.519 0.199 . . . . 0.0 110.562 179.748 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_exo -41.9 -28.14 0.71 Allowed 'Trans proline' 0 C--N 1.348 0.545 0 C-N-CA 123.026 2.484 . . . . 0.0 113.511 -179.35 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.885 ' CG1' HD12 ' A' ' 2' ' ' LEU . 3.3 pt -79.74 148.05 6.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 120.948 0.404 . . . . 0.0 110.868 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.459 ' HA2' ' CD1' ' A' ' 16' ' ' PHE . . . 141.19 -131.02 4.69 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.592 -179.877 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' TRP . . . . . 0.406 ' CB ' ' HD2' ' A' ' 17' ' ' PRO . 50.3 t-105 -114.95 -48.55 2.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.561 0.22 . . . . 0.0 111.535 -179.65 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -146.0 178.53 8.13 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.989 0.424 . . . . 0.0 111.033 -179.703 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.591 ' HA ' ' CD1' ' A' ' 14' ' ' TRP . 1.7 mt -58.64 158.44 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.5 -179.716 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.46 ' N ' HG22 ' A' ' 8' ' ' ILE . 4.3 tt0 -99.01 176.99 5.38 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.732 -179.873 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.434 ' N ' ' CD ' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -89.46 -49.73 0.39 Allowed Pre-proline 0 C--N 1.326 -0.429 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.148 179.932 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.434 ' CD ' ' N ' ' A' ' 10' ' ' ARG . 91.6 Cg_endo -81.21 -43.79 0.1 OUTLIER 'Trans proline' 0 N--CA 1.46 -0.482 0 C-N-CA 122.334 2.023 . . . . 0.0 112.505 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 17.5 p -177.7 144.1 0.36 Allowed 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.161 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 81.13 -143.83 24.31 Favored Glycine 0 N--CA 1.453 -0.224 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.802 179.681 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.591 ' CD1' ' HA ' ' A' ' 8' ' ' ILE . 11.0 m0 -120.98 174.73 6.44 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 110.406 -0.22 . . . . 0.0 110.406 179.848 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' TYR . . . . . 0.423 ' HB3' ' HG3' ' A' ' 9' ' ' GLU . 0.2 OUTLIER -134.59 -174.12 3.49 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.91 0.386 . . . . 0.0 111.349 -179.828 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 16' ' ' PHE . . . . . 0.468 ' CD2' ' N ' ' A' ' 16' ' ' PHE . 0.1 OUTLIER -140.46 99.65 7.02 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.8 -179.821 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.407 ' HD3' ' CE1' ' A' ' 15' ' ' TYR . 74.1 Cg_endo -76.02 111.84 3.36 Favored 'Trans proline' 0 C--N 1.345 0.353 0 C-N-CA 122.5 2.134 . . . . 0.0 112.231 -179.968 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 3.2 mp . . . . . 0 C--N 1.33 -0.246 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.115 179.983 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.34 0 N-CA-C 112.603 -0.199 . . . . 0.0 112.603 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.437 ' O ' ' HB2' ' A' ' 14' ' ' TRP . 4.1 mt -131.17 122.58 19.25 Favored Pre-proline 0 C--N 1.329 -0.284 0 N-CA-C 110.579 -0.156 . . . . 0.0 110.579 179.969 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 98.9 Cg_exo -42.46 -30.37 1.52 Allowed 'Trans proline' 0 C--N 1.35 0.607 0 C-N-CA 122.782 2.322 . . . . 0.0 112.949 -179.835 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.455 HD12 ' CZ ' ' A' ' 16' ' ' PHE . 3.9 pt -90.97 150.82 3.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.804 179.633 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.436 ' HA2' ' CD2' ' A' ' 16' ' ' PHE . . . 147.04 -112.23 0.59 Allowed Glycine 0 CA--C 1.518 0.258 0 C-N-CA 120.556 -0.83 . . . . 0.0 112.687 -179.882 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 56.5 t-105 -137.93 -46.05 0.53 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.556 0.217 . . . . 0.0 111.432 -179.639 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.535 ' CE2' HD12 ' A' ' 8' ' ' ILE . 64.4 t-105 -146.69 165.56 29.23 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.0 0.429 . . . . 0.0 111.678 -179.521 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.54 ' HA ' ' CD1' ' A' ' 14' ' ' TRP . 1.7 mt -57.43 158.6 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 115.726 -0.67 . . . . 0.0 111.868 -179.535 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.477 ' N ' HG22 ' A' ' 8' ' ' ILE . 4.5 mt-10 -96.44 -175.67 3.4 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.778 179.724 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.416 ' H ' ' HD2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -89.01 -56.46 0.28 Allowed Pre-proline 0 C--N 1.321 -0.663 0 CA-C-N 115.51 -0.768 . . . . 0.0 110.781 179.926 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.416 ' HD2' ' H ' ' A' ' 10' ' ' ARG . 55.3 Cg_endo -74.11 -55.28 0.09 OUTLIER 'Trans proline' 0 C--N 1.346 0.422 0 C-N-CA 122.051 1.834 . . . . 0.0 112.239 179.635 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 70.8 m -168.21 149.89 5.19 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.097 179.926 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 80.59 -162.66 45.57 Favored Glycine 0 C--N 1.331 0.28 0 C-N-CA 120.931 -0.652 . . . . 0.0 113.101 179.45 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.54 ' CD1' ' HA ' ' A' ' 8' ' ' ILE . 16.0 m0 -117.17 176.42 5.15 Favored 'General case' 0 C--N 1.332 -0.194 0 N-CA-C 110.203 -0.295 . . . . 0.0 110.203 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' TYR . . . . . 0.477 ' CZ ' ' HB3' ' A' ' 7' ' ' TRP . 7.5 p90 -134.71 168.49 18.93 Favored 'General case' 0 N--CA 1.463 0.191 0 CA-C-O 120.883 0.373 . . . . 0.0 111.339 179.793 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' PHE . . . . . 0.455 ' CZ ' HD12 ' A' ' 4' ' ' ILE . 2.8 m-85 -99.64 152.52 37.83 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.996 -179.862 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -75.72 119.11 5.32 Favored 'Trans proline' 0 C--N 1.345 0.35 0 C-N-CA 122.589 2.193 . . . . 0.0 112.289 179.911 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.2 tt . . . . . 0 C--N 1.329 -0.312 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.147 179.94 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.258 0 N-CA-C 112.653 -0.179 . . . . 0.0 112.653 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.485 ' O ' ' HB2' ' A' ' 14' ' ' TRP . 3.9 mt -125.16 123.39 25.32 Favored Pre-proline 0 C--N 1.331 -0.217 0 O-C-N 122.975 -0.132 . . . . 0.0 110.666 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 97.5 Cg_exo -41.33 -31.75 1.07 Allowed 'Trans proline' 0 C--N 1.349 0.574 0 C-N-CA 122.817 2.345 . . . . 0.0 112.992 -179.781 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.6 pt -92.26 150.6 3.78 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.016 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.437 ' HA2' ' CE1' ' A' ' 16' ' ' PHE . . . 144.36 -106.93 0.42 Allowed Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.616 -0.802 . . . . 0.0 112.874 179.827 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 57.4 t-105 -125.42 -64.55 1.07 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.729 0.3 . . . . 0.0 111.136 -179.603 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.72 ' CE3' HD12 ' A' ' 8' ' ' ILE . 1.1 m95 -144.06 -179.95 6.82 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.096 0.474 . . . . 0.0 111.097 -179.68 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.72 HD12 ' CE3' ' A' ' 7' ' ' TRP . 2.5 mp -54.93 158.26 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 115.683 -0.69 . . . . 0.0 111.98 -179.498 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.513 ' HG3' ' HB3' ' A' ' 15' ' ' TYR . 1.9 mt-10 -100.04 179.94 4.34 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.53 -0.759 . . . . 0.0 110.661 179.745 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.425 ' N ' ' HD2' ' A' ' 11' ' ' PRO . 3.3 mmp_? -89.25 -51.44 0.37 Allowed Pre-proline 0 C--N 1.324 -0.534 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.775 179.81 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.425 ' HD2' ' N ' ' A' ' 10' ' ' ARG . 90.8 Cg_endo -80.32 -44.23 0.11 Allowed 'Trans proline' 0 N--CA 1.462 -0.358 0 C-N-CA 122.322 2.015 . . . . 0.0 112.253 179.801 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 16.7 p -178.47 152.13 0.64 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.243 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 75.17 -153.35 44.87 Favored Glycine 0 C--N 1.332 0.325 0 C-N-CA 120.968 -0.634 . . . . 0.0 112.862 179.681 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.604 ' CD1' ' HA ' ' A' ' 8' ' ' ILE . 13.3 m0 -120.37 171.79 8.27 Favored 'General case' 0 C--N 1.332 -0.184 0 N-CA-C 110.292 -0.262 . . . . 0.0 110.292 179.807 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' TYR . . . . . 0.513 ' HB3' ' HG3' ' A' ' 9' ' ' GLU . 0.0 OUTLIER -129.21 161.96 28.96 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.74 0.305 . . . . 0.0 111.343 179.837 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 16' ' ' PHE . . . . . 0.437 ' CE1' ' HA2' ' A' ' 5' ' ' GLY . 28.4 m-85 -90.05 162.42 35.25 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.813 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -71.15 70.11 2.38 Favored 'Trans proline' 0 C--N 1.346 0.406 0 C-N-CA 122.468 2.112 . . . . 0.0 112.229 -179.881 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 19.8 tt . . . . . 0 C--N 1.328 -0.35 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.07 179.895 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.518 0.226 0 N-CA-C 112.597 -0.201 . . . . 0.0 112.597 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.59 HD13 HG13 ' A' ' 4' ' ' ILE . 0.2 OUTLIER -136.7 137.62 24.13 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 120.596 0.236 . . . . 0.0 110.599 179.991 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_exo -46.17 -28.42 5.5 Favored 'Trans proline' 0 C--N 1.347 0.476 0 C-N-CA 122.672 2.248 . . . . 0.0 112.752 -179.728 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.59 HG13 HD13 ' A' ' 2' ' ' LEU . 5.1 pt -80.07 153.39 4.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.03 179.892 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.453 ' HA2' ' CD2' ' A' ' 16' ' ' PHE . . . 138.16 -123.76 2.76 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.697 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 65.4 t-105 -127.02 -45.65 1.56 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.723 0.297 . . . . 0.0 111.281 -179.708 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 0.4 OUTLIER -146.84 179.94 7.23 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.157 0.504 . . . . 0.0 111.102 -179.52 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.589 ' HA ' ' CD1' ' A' ' 14' ' ' TRP . 1.5 mp -58.23 158.73 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.655 -0.702 . . . . 0.0 111.454 -179.873 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.462 ' N ' HG22 ' A' ' 8' ' ' ILE . 3.9 tt0 -101.2 175.95 5.41 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.718 -179.884 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.433 ' N ' ' CD ' ' A' ' 11' ' ' PRO . 9.6 ttp180 -89.56 -49.13 0.39 Allowed Pre-proline 0 C--N 1.326 -0.415 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.343 -179.738 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.433 ' CD ' ' N ' ' A' ' 10' ' ' ARG . 90.6 Cg_endo -81.08 -37.48 0.31 Allowed 'Trans proline' 0 C--N 1.347 0.47 0 C-N-CA 122.273 1.982 . . . . 0.0 112.536 -179.803 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER 176.45 149.76 0.13 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.036 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 72.02 -145.59 38.29 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.671 179.666 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.589 ' CD1' ' HA ' ' A' ' 8' ' ' ILE . 12.1 m0 -117.97 179.88 3.96 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.582 0.23 . . . . 0.0 110.49 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' TYR . . . . . 0.401 ' CD1' ' C ' ' A' ' 15' ' ' TYR . 0.0 OUTLIER -132.32 162.73 30.3 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.854 0.359 . . . . 0.0 111.203 179.987 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 16' ' ' PHE . . . . . 0.48 ' CE2' HD12 ' A' ' 4' ' ' ILE . 1.2 m-85 -90.4 146.05 33.76 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.934 -179.881 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 85.3 Cg_endo -78.51 -172.48 1.52 Allowed 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.66 2.24 . . . . 0.0 112.322 179.92 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 8.9 tp . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.11 179.962 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.545 ' C ' HD23 ' A' ' 2' ' ' LEU . . . . . . . . 0 N--CA 1.452 -0.295 0 N-CA-C 112.523 -0.231 . . . . 0.0 112.523 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.655 ' N ' HD23 ' A' ' 2' ' ' LEU . 0.1 OUTLIER -137.4 125.75 14.59 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 120.457 0.17 . . . . 0.0 110.833 179.966 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 80.2 Cg_exo -44.88 -29.66 3.83 Favored 'Trans proline' 0 C--N 1.348 0.531 0 C-N-CA 122.697 2.265 . . . . 0.0 112.73 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.4 pt -80.63 150.28 4.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.874 179.796 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 141.49 -117.22 1.18 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.498 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 60.1 t-105 -133.29 -44.94 0.84 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.68 0.276 . . . . 0.0 111.419 -179.813 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.66 ' CD2' HD12 ' A' ' 8' ' ' ILE . 0.3 OUTLIER -147.2 179.23 7.78 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 121.054 0.454 . . . . 0.0 111.189 -179.485 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.66 HD12 ' CD2' ' A' ' 7' ' ' TRP . 2.8 mp -57.69 158.86 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 115.848 -0.614 . . . . 0.0 111.467 -179.878 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.472 ' N ' HG22 ' A' ' 8' ' ' ILE . 4.2 tt0 -99.04 179.07 4.74 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.856 -179.882 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.452 ' N ' ' CD ' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -89.33 -47.97 0.41 Allowed Pre-proline 0 C--N 1.326 -0.456 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.456 -179.871 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.452 ' CD ' ' N ' ' A' ' 10' ' ' ARG . 93.2 Cg_endo -82.6 -43.7 0.08 OUTLIER 'Trans proline' 0 C--N 1.347 0.498 0 C-N-CA 122.348 2.032 . . . . 0.0 112.407 -179.808 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.1 p 179.59 142.06 0.13 Allowed 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.848 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 85.49 -143.25 19.98 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.523 179.941 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.606 ' CD1' ' HA ' ' A' ' 8' ' ' ILE . 7.9 m0 -121.87 179.06 4.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.588 0.232 . . . . 0.0 110.672 179.954 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' TYR . . . . . 0.407 ' HB3' ' HG3' ' A' ' 9' ' ' GLU . 0.1 OUTLIER -138.82 -178.22 5.22 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-O 120.878 0.37 . . . . 0.0 110.788 179.919 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 16' ' ' PHE . . . . . . . . . . . . . 3.7 m-85 -104.97 160.87 24.5 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.092 -179.838 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -75.83 -165.28 0.29 Allowed 'Trans proline' 0 C--N 1.345 0.357 0 C-N-CA 122.78 2.32 . . . . 0.0 112.273 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.5 mp . . . . . 0 C--N 1.33 -0.247 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.95 179.986 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.371 0 N-CA-C 112.524 -0.23 . . . . 0.0 112.524 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 15.1 mt -145.68 137.92 13.47 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 120.481 0.181 . . . . 0.0 110.87 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_exo -48.35 -27.4 9.87 Favored 'Trans proline' 0 C--N 1.346 0.442 0 C-N-CA 122.484 2.122 . . . . 0.0 112.492 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.734 HD12 ' HZ ' ' A' ' 16' ' ' PHE . 3.8 pt -86.86 152.56 3.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.907 179.856 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 143.66 -116.57 0.99 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.421 -179.86 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 61.9 t-105 -133.82 -47.16 0.8 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.709 0.29 . . . . 0.0 111.039 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 9.6 t-105 -149.93 176.39 10.8 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.914 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.558 ' HA ' ' CD1' ' A' ' 14' ' ' TRP . 4.1 mm -48.14 159.22 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.638 -179.901 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.422 ' HG3' ' HB3' ' A' ' 15' ' ' TYR . 3.0 tt0 -105.33 178.17 4.64 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.707 179.909 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.416 ' N ' ' CD ' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -89.41 -51.24 0.37 Allowed Pre-proline 0 C--N 1.326 -0.438 0 CA-C-N 115.975 -0.557 . . . . 0.0 111.187 -179.779 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.416 ' CD ' ' N ' ' A' ' 10' ' ' ARG . 72.0 Cg_endo -81.33 -48.5 0.06 OUTLIER 'Trans proline' 0 C--N 1.346 0.44 0 C-N-CA 122.293 1.995 . . . . 0.0 112.439 -179.892 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 67.6 m -166.57 157.08 12.19 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.957 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 59.51 -149.82 39.16 Favored Glycine 0 N--CA 1.452 -0.248 0 C-N-CA 120.862 -0.685 . . . . 0.0 112.648 179.764 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.558 ' CD1' ' HA ' ' A' ' 8' ' ' ILE . 30.2 m0 -109.92 179.4 4.12 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.591 0.234 . . . . 0.0 110.601 -179.861 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' TYR . . . . . 0.422 ' HB3' ' HG3' ' A' ' 9' ' ' GLU . 1.1 p90 -131.98 167.18 20.11 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.828 0.347 . . . . 0.0 110.984 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' PHE . . . . . 0.734 ' HZ ' HD12 ' A' ' 4' ' ' ILE . 10.5 m-85 -102.78 163.08 18.3 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.913 -179.963 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo -67.48 88.69 0.34 Allowed 'Trans proline' 0 C--N 1.346 0.409 0 C-N-CA 122.638 2.225 . . . . 0.0 112.327 179.893 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.9 mm . . . . . 0 C--N 1.327 -0.38 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.191 179.842 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.4 0 N-CA-C 112.478 -0.249 . . . . 0.0 112.478 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.3 mt -139.18 144.88 42.42 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 120.631 0.253 . . . . 0.0 110.831 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_exo -50.34 -24.93 12.71 Favored 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.575 2.184 . . . . 0.0 112.447 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.9 pt -79.8 154.39 4.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.055 179.855 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 134.88 -121.65 2.67 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.455 -179.863 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 36.0 t-105 -134.68 -44.19 0.75 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.685 0.278 . . . . 0.0 111.351 -179.84 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 0.5 OUTLIER -147.4 -179.32 6.77 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 121.095 0.474 . . . . 0.0 111.09 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.62 ' HA ' ' CD1' ' A' ' 14' ' ' TRP . 13.5 mt -53.75 158.53 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 115.688 -0.687 . . . . 0.0 111.718 -179.69 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.504 ' N ' HG22 ' A' ' 8' ' ' ILE . 3.6 tt0 -105.52 177.49 4.84 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.789 -0.642 . . . . 0.0 110.866 -179.703 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.448 ' N ' ' CD ' ' A' ' 11' ' ' PRO . 12.3 tpp180 -89.61 -46.59 0.41 Allowed Pre-proline 0 C--N 1.327 -0.389 0 CA-C-N 115.797 -0.638 . . . . 0.0 111.932 -179.574 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.448 ' CD ' ' N ' ' A' ' 10' ' ' ARG . 71.8 Cg_endo -80.69 -48.09 0.07 OUTLIER 'Trans proline' 0 C--N 1.349 0.582 0 C-N-CA 122.209 1.939 . . . . 0.0 112.804 -179.475 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 4.3 p -179.3 129.04 0.1 Allowed 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.93 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 96.52 -141.33 15.54 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.455 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.62 ' CD1' ' HA ' ' A' ' 8' ' ' ILE . 10.0 m0 -120.48 174.78 6.34 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.736 0.303 . . . . 0.0 110.778 179.92 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' TYR . . . . . 0.419 ' CE1' HG22 ' A' ' 18' ' ' ILE . 0.1 OUTLIER -132.38 177.73 7.37 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.383 -0.372 . . . . 0.0 110.596 179.951 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 16' ' ' PHE . . . . . 0.401 ' O ' ' CE1' ' A' ' 15' ' ' TYR . 26.1 m-85 -89.77 160.9 40.25 Favored Pre-proline 0 C--N 1.328 -0.365 0 CA-C-N 116.418 -0.355 . . . . 0.0 111.025 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 68.2 Cg_endo -74.49 76.24 3.23 Favored 'Trans proline' 0 C--N 1.343 0.286 0 C-N-CA 122.722 2.281 . . . . 0.0 112.238 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.419 HG22 ' CE1' ' A' ' 15' ' ' TYR . 7.5 tp . . . . . 0 C--N 1.33 -0.281 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.076 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.388 0 N-CA-C 112.793 -0.123 . . . . 0.0 112.793 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 15.0 mt -140.6 142.63 29.55 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-O 120.507 0.194 . . . . 0.0 110.858 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 81.2 Cg_exo -48.02 -27.94 9.71 Favored 'Trans proline' 0 C--N 1.346 0.404 0 C-N-CA 122.655 2.237 . . . . 0.0 112.53 -179.834 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 8.2 pt -83.39 160.23 3.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.8 179.804 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 133.39 -121.62 2.88 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.653 -0.785 . . . . 0.0 112.687 -179.911 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 70.9 t-105 -128.41 -49.45 1.29 Allowed 'General case' 0 C--N 1.331 -0.203 0 N-CA-C 111.599 0.222 . . . . 0.0 111.599 -179.697 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.666 ' CD1' HD12 ' A' ' 8' ' ' ILE . 1.6 t-105 -148.87 175.1 11.55 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.898 0.38 . . . . 0.0 111.199 -179.447 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.666 HD12 ' CD1' ' A' ' 7' ' ' TRP . 2.2 mp -48.77 155.46 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.622 -179.738 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.49 ' HG3' ' HB3' ' A' ' 15' ' ' TYR . 2.8 tt0 -100.69 177.93 4.85 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.896 -0.593 . . . . 0.0 111.136 -179.681 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.431 ' N ' ' CD ' ' A' ' 11' ' ' PRO . 1.9 tpt180 -89.43 -50.03 0.38 Allowed Pre-proline 0 C--N 1.326 -0.423 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.212 179.961 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.431 ' CD ' ' N ' ' A' ' 10' ' ' ARG . 89.9 Cg_endo -82.89 -39.67 0.13 Allowed 'Trans proline' 0 C--N 1.348 0.512 0 C-N-CA 122.491 2.127 . . . . 0.0 112.544 -179.804 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 17.9 p -177.52 157.77 1.31 Allowed 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.056 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 59.82 -148.5 42.23 Favored Glycine 0 N--CA 1.453 -0.215 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.517 179.909 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.598 ' CD1' ' HA ' ' A' ' 8' ' ' ILE . 30.5 m0 -115.54 174.96 5.74 Favored 'General case' 0 C--N 1.332 -0.186 0 C-N-CA 122.183 0.193 . . . . 0.0 110.513 179.96 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' TYR . . . . . 0.496 ' CD2' ' O ' ' A' ' 8' ' ' ILE . 3.3 p90 -122.08 166.6 14.28 Favored 'General case' 0 N--CA 1.462 0.172 0 CA-C-O 120.794 0.33 . . . . 0.0 110.688 179.151 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' PHE . . . . . . . . . . . . . 1.8 m-85 -91.19 148.02 36.88 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.899 179.843 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -72.65 71.42 3.25 Favored 'Trans proline' 0 C--N 1.345 0.363 0 C-N-CA 122.563 2.175 . . . . 0.0 112.487 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 40.9 mt . . . . . 0 C--N 1.328 -0.353 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.049 -179.903 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.333 0 N-CA-C 112.425 -0.27 . . . . 0.0 112.425 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.424 ' O ' ' HB2' ' A' ' 14' ' ' TRP . 0.3 OUTLIER -128.48 145.35 55.58 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 120.522 0.201 . . . . 0.0 110.614 179.929 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 82.0 Cg_exo -44.37 -28.37 2.5 Favored 'Trans proline' 0 C--N 1.347 0.467 0 C-N-CA 122.705 2.27 . . . . 0.0 112.755 -179.848 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.703 HD12 ' CZ ' ' A' ' 16' ' ' PHE . 3.4 pt -79.84 151.85 4.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.765 179.725 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.413 ' HA2' ' CZ ' ' A' ' 16' ' ' PHE . . . 133.81 -120.5 2.53 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.578 -179.948 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 24.2 t-105 -121.74 -64.61 1.2 Allowed 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 120.642 0.258 . . . . 0.0 111.31 -179.75 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.741 ' CD2' HD12 ' A' ' 8' ' ' ILE . 0.0 OUTLIER -140.7 177.19 8.2 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.846 0.355 . . . . 0.0 111.154 -179.582 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.741 HD12 ' CD2' ' A' ' 7' ' ' TRP . 2.5 mp -46.19 155.53 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.435 -179.77 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.433 ' N ' HG22 ' A' ' 8' ' ' ILE . 3.3 tt0 -102.81 179.82 4.17 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.091 -179.534 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.439 ' N ' ' CD ' ' A' ' 11' ' ' PRO . 7.7 mtt-85 -89.36 -48.41 0.4 Allowed Pre-proline 0 C--N 1.325 -0.493 0 CA-C-N 115.581 -0.736 . . . . 0.0 111.149 179.908 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.439 ' CD ' ' N ' ' A' ' 10' ' ' ARG . 93.1 Cg_endo -82.25 -40.93 0.13 Allowed 'Trans proline' 0 C--N 1.346 0.446 0 C-N-CA 122.352 2.035 . . . . 0.0 112.424 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.2 p 175.87 144.54 0.07 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.992 179.912 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 81.11 -142.89 23.57 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.708 179.812 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.622 ' CD1' ' HA ' ' A' ' 8' ' ' ILE . 13.4 m0 -123.07 168.7 12.03 Favored 'General case' 0 CA--C 1.53 0.207 0 N-CA-C 110.276 -0.268 . . . . 0.0 110.276 179.91 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' TYR . . . . . 0.442 ' CD2' ' O ' ' A' ' 8' ' ' ILE . 4.1 p90 -114.95 177.58 4.6 Favored 'General case' 0 N--CA 1.463 0.218 0 CA-C-O 120.845 0.355 . . . . 0.0 110.885 179.442 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' PHE . . . . . 0.703 ' CZ ' HD12 ' A' ' 4' ' ' ILE . 5.4 m-85 -119.83 152.78 54.25 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.743 179.901 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -75.81 58.95 5.57 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.573 2.182 . . . . 0.0 112.353 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 5.6 tp . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.054 -179.915 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.318 0 N-CA-C 112.417 -0.273 . . . . 0.0 112.417 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.452 HD12 ' N ' ' A' ' 2' ' ' LEU . 0.0 OUTLIER -130.71 142.26 44.9 Favored Pre-proline 0 C--N 1.329 -0.298 0 N-CA-C 110.521 -0.177 . . . . 0.0 110.521 179.877 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.553 ' O ' HG23 ' A' ' 4' ' ' ILE . 16.6 Cg_exo -67.42 59.58 0.72 Allowed 'Trans proline' 0 C--N 1.347 0.484 0 C-N-CA 122.664 2.243 . . . . 0.0 112.517 -179.858 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.553 HG23 ' O ' ' A' ' 3' ' ' PRO . 12.2 pt -160.09 167.28 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.727 179.876 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.432 ' HA2' ' CD1' ' A' ' 16' ' ' PHE . . . 116.64 -99.22 0.84 Allowed Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.588 -0.815 . . . . 0.0 112.591 179.897 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 48.9 t-105 -149.39 -39.31 0.15 Allowed 'General case' 0 C--N 1.33 -0.246 0 N-CA-C 111.779 0.289 . . . . 0.0 111.779 -179.714 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.486 ' CD1' HD12 ' A' ' 8' ' ' ILE . 1.4 t-105 -145.13 178.81 7.79 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 121.184 0.516 . . . . 0.0 111.422 -179.437 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.576 ' HA ' ' CD1' ' A' ' 14' ' ' TRP . 1.5 mt -62.49 158.5 3.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.512 -0.767 . . . . 0.0 111.36 -179.829 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.448 ' N ' HG22 ' A' ' 8' ' ' ILE . 4.3 tt0 -95.9 176.46 6.11 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.916 -0.583 . . . . 0.0 110.849 179.887 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.473 ' N ' ' CD ' ' A' ' 11' ' ' PRO . 10.3 ttt180 -89.43 -45.47 0.42 Allowed Pre-proline 0 C--N 1.326 -0.416 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.567 -179.86 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.473 ' CD ' ' N ' ' A' ' 10' ' ' ARG . 92.1 Cg_endo -82.5 -44.13 0.08 OUTLIER 'Trans proline' 0 C--N 1.349 0.572 0 C-N-CA 122.129 1.886 . . . . 0.0 112.388 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 21.4 p 177.17 133.37 0.06 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.853 179.894 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 97.13 -142.2 16.04 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.675 179.868 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.576 ' CD1' ' HA ' ' A' ' 8' ' ' ILE . 5.8 m0 -125.74 -177.71 4.01 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.608 0.242 . . . . 0.0 110.644 -179.965 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' TYR . . . . . 0.416 ' HB3' ' HG3' ' A' ' 9' ' ' GLU . 0.1 OUTLIER -147.96 170.96 16.58 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 120.807 0.337 . . . . 0.0 111.106 179.93 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 16' ' ' PHE . . . . . 0.432 ' CD1' ' HA2' ' A' ' 5' ' ' GLY . 29.3 m-85 -96.64 161.63 25.99 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.877 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -73.25 154.22 51.44 Favored 'Trans proline' 0 C--N 1.344 0.317 0 C-N-CA 122.536 2.157 . . . . 0.0 112.282 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 29.8 mm . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.13 179.968 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.418 0 N-CA-C 112.658 -0.177 . . . . 0.0 112.658 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.436 ' O ' ' HB2' ' A' ' 14' ' ' TRP . 0.5 OUTLIER -125.43 130.65 24.05 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 120.397 0.141 . . . . 0.0 110.648 179.878 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 99.6 Cg_exo -42.03 -31.24 1.48 Allowed 'Trans proline' 0 C--N 1.348 0.532 0 C-N-CA 122.785 2.323 . . . . 0.0 112.854 -179.826 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.423 HD12 ' CZ ' ' A' ' 16' ' ' PHE . 3.5 pt -83.29 149.64 4.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.86 179.754 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 141.72 -111.16 0.68 Allowed Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.544 -0.836 . . . . 0.0 112.581 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 73.5 t-105 -133.4 -59.32 0.87 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.507 0.194 . . . . 0.0 111.512 -179.617 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 0.8 OUTLIER -135.62 179.05 6.57 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 121.051 0.453 . . . . 0.0 111.489 -179.359 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.542 ' HA ' ' CD1' ' A' ' 14' ' ' TRP . 6.0 mt -65.64 153.64 8.17 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 115.753 -0.658 . . . . 0.0 111.332 -179.848 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -93.44 179.97 5.23 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.692 -0.685 . . . . 0.0 111.115 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.427 ' N ' ' HD2' ' A' ' 11' ' ' PRO . 3.3 ttt180 -89.44 -52.29 0.35 Allowed Pre-proline 0 C--N 1.325 -0.463 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.2 -179.786 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.427 ' HD2' ' N ' ' A' ' 10' ' ' ARG . 72.8 Cg_endo -78.04 -41.27 0.31 Allowed 'Trans proline' 0 C--N 1.347 0.46 0 C-N-CA 122.339 2.026 . . . . 0.0 112.465 -179.905 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER 175.69 145.73 0.08 Allowed 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.1 179.872 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 83.89 -152.26 28.4 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.857 179.803 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.542 ' CD1' ' HA ' ' A' ' 8' ' ' ILE . 9.1 m0 -123.53 173.53 7.98 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 110.407 -0.22 . . . . 0.0 110.407 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' TYR . . . . . 0.436 ' CD2' ' O ' ' A' ' 8' ' ' ILE . 6.6 p90 -125.71 164.71 20.05 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.698 0.285 . . . . 0.0 110.698 179.691 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' PHE . . . . . 0.423 ' CZ ' HD12 ' A' ' 4' ' ' ILE . 11.4 m-85 -90.05 151.55 45.16 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.853 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.785 ' C ' HD12 ' A' ' 18' ' ' ILE . 73.2 Cg_endo -77.74 160.71 31.03 Favored 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.691 2.261 . . . . 0.0 112.607 -179.898 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.785 HD12 ' C ' ' A' ' 17' ' ' PRO . 2.7 mp . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.743 179.772 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.434 ' N ' ' O ' ' A' ' 14' ' ' TRP . . . . . . . . 0 N--CA 1.452 -0.249 0 N-CA-C 112.592 -0.203 . . . . 0.0 112.592 . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.897 HD12 HG13 ' A' ' 4' ' ' ILE . 0.0 OUTLIER -134.58 130.85 20.04 Favored Pre-proline 0 C--N 1.331 -0.211 0 CA-C-O 120.458 0.17 . . . . 0.0 110.572 -179.93 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 92.0 Cg_exo -42.45 -29.19 1.18 Allowed 'Trans proline' 0 C--N 1.347 0.496 0 C-N-CA 122.905 2.403 . . . . 0.0 113.209 -179.555 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.897 HG13 HD12 ' A' ' 2' ' ' LEU . 4.1 pt -79.85 150.49 4.96 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 116.531 -0.304 . . . . 0.0 110.772 179.843 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.459 ' HA2' ' CE2' ' A' ' 16' ' ' PHE . . . 141.01 -132.47 5.39 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.538 -179.713 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' TRP . . . . . 0.419 ' HB2' ' HD3' ' A' ' 17' ' ' PRO . 35.0 t-105 -119.29 -39.66 2.88 Favored 'General case' 0 C--N 1.332 -0.194 0 N-CA-C 111.673 0.249 . . . . 0.0 111.673 -179.633 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 2.4 t-105 -150.15 175.54 11.65 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.956 0.408 . . . . 0.0 111.101 -179.611 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.566 ' HA ' ' CD1' ' A' ' 14' ' ' TRP . 2.7 mp -58.06 159.12 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.389 -179.865 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.474 ' N ' HG22 ' A' ' 8' ' ' ILE . 3.9 tt0 -101.34 176.38 5.26 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.728 -179.892 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.436 ' N ' ' CD ' ' A' ' 11' ' ' PRO . 2.3 tpt180 -89.59 -48.43 0.4 Allowed Pre-proline 0 C--N 1.327 -0.392 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.36 -179.782 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.436 ' CD ' ' N ' ' A' ' 10' ' ' ARG . 72.7 Cg_endo -80.15 -51.2 0.05 OUTLIER 'Trans proline' 0 C--N 1.347 0.5 0 C-N-CA 122.154 1.903 . . . . 0.0 112.523 -179.862 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -169.75 140.79 2.18 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.048 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 80.49 -145.85 26.84 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.931 -0.652 . . . . 0.0 112.724 179.718 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.566 ' CD1' ' HA ' ' A' ' 8' ' ' ILE . 15.2 m0 -115.6 -179.26 3.59 Favored 'General case' 0 C--N 1.331 -0.231 0 N-CA-C 110.421 -0.214 . . . . 0.0 110.421 -179.97 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' TYR . . . . . 0.408 ' C ' ' CD2' ' A' ' 15' ' ' TYR . 0.1 OUTLIER -129.81 173.96 10.17 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.986 0.422 . . . . 0.0 111.531 -179.679 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 16' ' ' PHE . . . . . 0.459 ' CE2' ' HA2' ' A' ' 5' ' ' GLY . 0.8 OUTLIER -122.41 137.17 27.3 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.843 -179.971 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.49 ' O ' HD13 ' A' ' 18' ' ' ILE . 96.4 Cg_endo -80.34 150.65 19.88 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.579 2.186 . . . . 0.0 112.339 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.49 HD13 ' O ' ' A' ' 17' ' ' PRO . 26.1 mm . . . . . 0 C--N 1.33 -0.248 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.026 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.287 0 N-CA-C 112.693 -0.163 . . . . 0.0 112.693 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.449 ' O ' ' HB2' ' A' ' 14' ' ' TRP . 1.0 OUTLIER -129.95 127.62 22.76 Favored Pre-proline 0 C--N 1.329 -0.306 0 N-CA-C 110.584 -0.154 . . . . 0.0 110.584 -179.982 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 87.8 Cg_exo -41.62 -30.74 1.05 Allowed 'Trans proline' 0 C--N 1.348 0.544 0 C-N-CA 122.811 2.341 . . . . 0.0 112.96 -179.623 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.5 pt -90.74 150.49 3.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.99 179.827 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 142.86 -104.11 0.35 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.562 -0.827 . . . . 0.0 112.93 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . 0.419 ' N ' ' O ' ' A' ' 15' ' ' TYR . 50.6 t-105 -134.41 -63.73 0.71 Allowed 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 120.589 0.233 . . . . 0.0 111.481 -179.313 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 2.2 t-105 -139.27 177.8 7.65 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-O 121.024 0.44 . . . . 0.0 111.477 -179.158 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.524 ' HA ' ' CD1' ' A' ' 14' ' ' TRP . 6.9 mt -61.15 155.76 3.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.777 -0.647 . . . . 0.0 111.832 -179.581 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.437 ' HG3' ' HB3' ' A' ' 15' ' ' TYR . 4.6 mt-10 -97.72 -175.97 3.33 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.017 179.835 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.436 ' H ' ' HD2' ' A' ' 11' ' ' PRO . 11.9 mtm-85 -89.34 -56.55 0.28 Allowed Pre-proline 0 C--N 1.322 -0.601 0 CA-C-N 115.43 -0.805 . . . . 0.0 110.989 179.909 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.436 ' HD2' ' H ' ' A' ' 10' ' ' ARG . 62.2 Cg_endo -73.79 -44.79 0.44 Allowed 'Trans proline' 0 C--N 1.346 0.429 0 C-N-CA 122.275 1.983 . . . . 0.0 112.386 179.805 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 5.6 p 177.31 149.88 0.16 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.018 -0.537 . . . . 0.0 111.004 179.915 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 81.63 -160.87 41.93 Favored Glycine 0 C--N 1.331 0.301 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.845 179.776 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.524 ' CD1' ' HA ' ' A' ' 8' ' ' ILE . 14.4 m0 -119.4 169.99 9.53 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 110.216 -0.29 . . . . 0.0 110.216 179.909 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . 0.437 ' HB3' ' HG3' ' A' ' 9' ' ' GLU . 19.7 p90 -129.54 170.49 13.68 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-O 120.675 0.274 . . . . 0.0 110.87 179.712 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' PHE . . . . . . . . . . . . . 37.5 m-85 -89.77 155.98 47.57 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.2 -179.793 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -84.78 50.85 3.03 Favored 'Trans proline' 0 N--CA 1.462 -0.36 0 C-N-CA 122.854 2.369 . . . . 0.0 112.593 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 34.7 mt . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.166 -179.928 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.299 0 N-CA-C 112.457 -0.257 . . . . 0.0 112.457 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.898 HD12 HG13 ' A' ' 4' ' ' ILE . 0.1 OUTLIER -128.61 130.06 23.51 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-O 120.469 0.176 . . . . 0.0 110.592 179.887 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_exo -46.36 -26.67 4.19 Favored 'Trans proline' 0 C--N 1.348 0.525 0 C-N-CA 122.544 2.162 . . . . 0.0 112.619 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.898 HG13 HD12 ' A' ' 2' ' ' LEU . 3.3 pt -79.77 149.5 5.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.548 179.662 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.447 ' HA2' ' CD1' ' A' ' 16' ' ' PHE . . . 139.1 -126.41 3.36 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.176 -179.585 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . 0.459 ' HB3' ' CD ' ' A' ' 17' ' ' PRO . 43.4 t-105 -129.66 -44.09 1.23 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.574 0.226 . . . . 0.0 111.59 -179.943 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 1.0 OUTLIER -140.27 177.38 8.04 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.257 0.551 . . . . 0.0 111.689 -179.413 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.518 ' HA ' ' CD1' ' A' ' 14' ' ' TRP . 2.9 mt -67.04 158.84 5.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.265 -0.88 . . . . 0.0 111.844 -179.641 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.495 ' N ' HG22 ' A' ' 8' ' ' ILE . 2.0 mt-10 -93.91 -175.51 3.74 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.615 -0.721 . . . . 0.0 110.967 179.832 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -89.24 -54.86 0.31 Allowed Pre-proline 0 C--N 1.323 -0.586 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.915 -179.902 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_endo -80.4 -41.23 0.17 Allowed 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.403 2.068 . . . . 0.0 112.33 179.883 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER 179.97 154.68 0.56 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.057 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 76.94 -157.41 47.02 Favored Glycine 0 CA--C 1.516 0.148 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.653 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.518 ' CD1' ' HA ' ' A' ' 8' ' ' ILE . 11.0 m0 -120.56 -177.35 3.44 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 110.266 -0.272 . . . . 0.0 110.266 179.876 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . 0.437 ' HB3' ' HG3' ' A' ' 9' ' ' GLU . 8.3 p90 -143.45 168.5 19.68 Favored 'General case' 0 CA--C 1.529 0.137 0 CA-C-O 120.939 0.399 . . . . 0.0 111.656 179.887 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' PHE . . . . . 0.638 ' HE1' HD12 ' A' ' 4' ' ' ILE . 0.3 OUTLIER -113.3 96.13 38.22 Favored Pre-proline 0 C--N 1.331 -0.233 0 CA-C-N 115.802 -0.636 . . . . 0.0 110.847 -179.769 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.564 ' O ' HD13 ' A' ' 18' ' ' ILE . 51.8 Cg_endo -69.25 -171.17 0.41 Allowed 'Trans proline' 0 C--N 1.345 0.35 0 C-N-CA 122.571 2.181 . . . . 0.0 112.417 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.564 HD13 ' O ' ' A' ' 17' ' ' PRO . 29.1 mm . . . . . 0 C--N 1.331 -0.205 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.036 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.238 0 N-CA-C 112.586 -0.206 . . . . 0.0 112.586 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.502 ' O ' ' HB2' ' A' ' 14' ' ' TRP . 3.8 mp -116.47 112.9 41.01 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-N 116.508 0.154 . . . . 0.0 110.859 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_exo -41.39 -30.16 0.8 Allowed 'Trans proline' 0 C--N 1.35 0.624 0 C-N-CA 122.852 2.368 . . . . 0.0 113.197 -179.821 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.4 pt -92.74 148.07 4.96 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 116.485 -0.325 . . . . 0.0 110.594 179.542 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.436 ' HA2' ' CE1' ' A' ' 16' ' ' PHE . . . 145.71 -105.93 0.36 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.563 -0.827 . . . . 0.0 112.934 -179.792 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 60.9 t-105 -129.83 -63.07 0.93 Allowed 'General case' 0 CA--C 1.53 0.191 0 N-CA-C 111.851 0.315 . . . . 0.0 111.851 -179.26 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.451 ' HB3' ' CZ ' ' A' ' 15' ' ' TYR . 35.3 t-105 -138.42 173.06 12.0 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.741 0.305 . . . . 0.0 111.249 -179.036 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.543 ' HA ' ' CD1' ' A' ' 14' ' ' TRP . 7.4 mt -57.3 154.97 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.406 -179.927 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.411 ' N ' HG22 ' A' ' 8' ' ' ILE . 2.2 tt0 -89.85 179.26 6.03 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.625 -0.716 . . . . 0.0 110.725 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.427 ' N ' ' CD ' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -89.01 -49.56 0.4 Allowed Pre-proline 0 C--N 1.324 -0.523 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.968 179.883 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.427 ' CD ' ' N ' ' A' ' 10' ' ' ARG . 95.3 Cg_endo -81.38 -38.21 0.25 Allowed 'Trans proline' 0 C--N 1.347 0.5 0 C-N-CA 122.16 1.906 . . . . 0.0 112.267 179.69 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.4 p 172.56 144.81 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.925 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 87.85 -147.55 20.49 Favored Glycine 0 CA--C 1.518 0.26 0 C-N-CA 120.887 -0.673 . . . . 0.0 112.636 179.804 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.543 ' CD1' ' HA ' ' A' ' 8' ' ' ILE . 7.0 m0 -127.69 177.44 6.8 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 110.191 -0.3 . . . . 0.0 110.191 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . 0.451 ' CZ ' ' HB3' ' A' ' 7' ' ' TRP . 6.1 p90 -135.89 174.96 10.03 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-O 120.909 0.385 . . . . 0.0 111.276 179.679 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' PHE . . . . . 0.436 ' CE1' ' HA2' ' A' ' 5' ' ' GLY . 89.6 m-85 -113.07 158.78 36.97 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.647 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -72.15 135.81 25.73 Favored 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.427 2.085 . . . . 0.0 112.296 -179.916 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 3.3 tt . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.158 -179.912 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.27 0 N-CA-C 112.486 -0.246 . . . . 0.0 112.486 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.885 HD12 ' CG1' ' A' ' 4' ' ' ILE . 0.2 OUTLIER -127.03 136.21 28.52 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 120.519 0.199 . . . . 0.0 110.562 179.748 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_exo -41.9 -28.14 0.71 Allowed 'Trans proline' 0 C--N 1.348 0.545 0 C-N-CA 123.026 2.484 . . . . 0.0 113.511 -179.35 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.885 ' CG1' HD12 ' A' ' 2' ' ' LEU . 3.3 pt -79.74 148.05 6.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 120.948 0.404 . . . . 0.0 110.868 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.459 ' HA2' ' CD1' ' A' ' 16' ' ' PHE . . . 141.19 -131.02 4.69 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.592 -179.877 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . 0.406 ' CB ' ' HD2' ' A' ' 17' ' ' PRO . 50.3 t-105 -114.95 -48.55 2.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.561 0.22 . . . . 0.0 111.535 -179.65 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -146.0 178.53 8.13 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.989 0.424 . . . . 0.0 111.033 -179.703 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.591 ' HA ' ' CD1' ' A' ' 14' ' ' TRP . 1.7 mt -58.64 158.44 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.5 -179.716 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.46 ' N ' HG22 ' A' ' 8' ' ' ILE . 4.3 tt0 -99.01 176.99 5.38 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.732 -179.873 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.434 ' N ' ' CD ' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -89.46 -49.73 0.39 Allowed Pre-proline 0 C--N 1.326 -0.429 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.148 179.932 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.434 ' CD ' ' N ' ' A' ' 10' ' ' ARG . 91.6 Cg_endo -81.21 -43.79 0.1 OUTLIER 'Trans proline' 0 N--CA 1.46 -0.482 0 C-N-CA 122.334 2.023 . . . . 0.0 112.505 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 17.5 p -177.7 144.1 0.36 Allowed 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.161 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 81.13 -143.83 24.31 Favored Glycine 0 N--CA 1.453 -0.224 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.802 179.681 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.591 ' CD1' ' HA ' ' A' ' 8' ' ' ILE . 11.0 m0 -120.98 174.73 6.44 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 110.406 -0.22 . . . . 0.0 110.406 179.848 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . 0.423 ' HB3' ' HG3' ' A' ' 9' ' ' GLU . 0.2 OUTLIER -134.59 -174.12 3.49 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.91 0.386 . . . . 0.0 111.349 -179.828 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' PHE . . . . . 0.468 ' CD2' ' N ' ' A' ' 16' ' ' PHE . 0.1 OUTLIER -140.46 99.65 7.02 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.8 -179.821 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.407 ' HD3' ' CE1' ' A' ' 15' ' ' TYR . 74.1 Cg_endo -76.02 111.84 3.36 Favored 'Trans proline' 0 C--N 1.345 0.353 0 C-N-CA 122.5 2.134 . . . . 0.0 112.231 -179.968 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 3.2 mp . . . . . 0 C--N 1.33 -0.246 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.115 179.983 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.34 0 N-CA-C 112.603 -0.199 . . . . 0.0 112.603 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.437 ' O ' ' HB2' ' A' ' 14' ' ' TRP . 4.1 mt -131.17 122.58 19.25 Favored Pre-proline 0 C--N 1.329 -0.284 0 N-CA-C 110.579 -0.156 . . . . 0.0 110.579 179.969 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 98.9 Cg_exo -42.46 -30.37 1.52 Allowed 'Trans proline' 0 C--N 1.35 0.607 0 C-N-CA 122.782 2.322 . . . . 0.0 112.949 -179.835 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.455 HD12 ' CZ ' ' A' ' 16' ' ' PHE . 3.9 pt -90.97 150.82 3.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.804 179.633 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.436 ' HA2' ' CD2' ' A' ' 16' ' ' PHE . . . 147.04 -112.23 0.59 Allowed Glycine 0 CA--C 1.518 0.258 0 C-N-CA 120.556 -0.83 . . . . 0.0 112.687 -179.882 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 56.5 t-105 -137.93 -46.05 0.53 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.556 0.217 . . . . 0.0 111.432 -179.639 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.535 ' CE2' HD12 ' A' ' 8' ' ' ILE . 64.4 t-105 -146.69 165.56 29.23 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.0 0.429 . . . . 0.0 111.678 -179.521 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.54 ' HA ' ' CD1' ' A' ' 14' ' ' TRP . 1.7 mt -57.43 158.6 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 115.726 -0.67 . . . . 0.0 111.868 -179.535 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.477 ' N ' HG22 ' A' ' 8' ' ' ILE . 4.5 mt-10 -96.44 -175.67 3.4 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.778 179.724 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.416 ' H ' ' HD2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -89.01 -56.46 0.28 Allowed Pre-proline 0 C--N 1.321 -0.663 0 CA-C-N 115.51 -0.768 . . . . 0.0 110.781 179.926 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.416 ' HD2' ' H ' ' A' ' 10' ' ' ARG . 55.3 Cg_endo -74.11 -55.28 0.09 OUTLIER 'Trans proline' 0 C--N 1.346 0.422 0 C-N-CA 122.051 1.834 . . . . 0.0 112.239 179.635 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 70.8 m -168.21 149.89 5.19 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.097 179.926 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 80.59 -162.66 45.57 Favored Glycine 0 C--N 1.331 0.28 0 C-N-CA 120.931 -0.652 . . . . 0.0 113.101 179.45 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.54 ' CD1' ' HA ' ' A' ' 8' ' ' ILE . 16.0 m0 -117.17 176.42 5.15 Favored 'General case' 0 C--N 1.332 -0.194 0 N-CA-C 110.203 -0.295 . . . . 0.0 110.203 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . 0.477 ' CZ ' ' HB3' ' A' ' 7' ' ' TRP . 7.5 p90 -134.71 168.49 18.93 Favored 'General case' 0 N--CA 1.463 0.191 0 CA-C-O 120.883 0.373 . . . . 0.0 111.339 179.793 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' PHE . . . . . 0.455 ' CZ ' HD12 ' A' ' 4' ' ' ILE . 2.8 m-85 -99.64 152.52 37.83 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.996 -179.862 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -75.72 119.11 5.32 Favored 'Trans proline' 0 C--N 1.345 0.35 0 C-N-CA 122.589 2.193 . . . . 0.0 112.289 179.911 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.2 tt . . . . . 0 C--N 1.329 -0.312 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.147 179.94 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.258 0 N-CA-C 112.653 -0.179 . . . . 0.0 112.653 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.485 ' O ' ' HB2' ' A' ' 14' ' ' TRP . 3.9 mt -125.16 123.39 25.32 Favored Pre-proline 0 C--N 1.331 -0.217 0 O-C-N 122.975 -0.132 . . . . 0.0 110.666 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 97.5 Cg_exo -41.33 -31.75 1.07 Allowed 'Trans proline' 0 C--N 1.349 0.574 0 C-N-CA 122.817 2.345 . . . . 0.0 112.992 -179.781 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.6 pt -92.26 150.6 3.78 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.016 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.437 ' HA2' ' CE1' ' A' ' 16' ' ' PHE . . . 144.36 -106.93 0.42 Allowed Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.616 -0.802 . . . . 0.0 112.874 179.827 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 57.4 t-105 -125.42 -64.55 1.07 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.729 0.3 . . . . 0.0 111.136 -179.603 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.72 ' CE3' HD12 ' A' ' 8' ' ' ILE . 1.1 m95 -144.06 -179.95 6.82 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.096 0.474 . . . . 0.0 111.097 -179.68 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.72 HD12 ' CE3' ' A' ' 7' ' ' TRP . 2.5 mp -54.93 158.26 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 115.683 -0.69 . . . . 0.0 111.98 -179.498 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.513 ' HG3' ' HB3' ' A' ' 15' ' ' TYR . 1.9 mt-10 -100.04 179.94 4.34 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.53 -0.759 . . . . 0.0 110.661 179.745 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.425 ' N ' ' HD2' ' A' ' 11' ' ' PRO . 3.3 mmp_? -89.25 -51.44 0.37 Allowed Pre-proline 0 C--N 1.324 -0.534 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.775 179.81 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.425 ' HD2' ' N ' ' A' ' 10' ' ' ARG . 90.8 Cg_endo -80.32 -44.23 0.11 Allowed 'Trans proline' 0 N--CA 1.462 -0.358 0 C-N-CA 122.322 2.015 . . . . 0.0 112.253 179.801 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 16.7 p -178.47 152.13 0.64 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.243 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 75.17 -153.35 44.87 Favored Glycine 0 C--N 1.332 0.325 0 C-N-CA 120.968 -0.634 . . . . 0.0 112.862 179.681 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.604 ' CD1' ' HA ' ' A' ' 8' ' ' ILE . 13.3 m0 -120.37 171.79 8.27 Favored 'General case' 0 C--N 1.332 -0.184 0 N-CA-C 110.292 -0.262 . . . . 0.0 110.292 179.807 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . 0.513 ' HB3' ' HG3' ' A' ' 9' ' ' GLU . 0.0 OUTLIER -129.21 161.96 28.96 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.74 0.305 . . . . 0.0 111.343 179.837 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' PHE . . . . . 0.437 ' CE1' ' HA2' ' A' ' 5' ' ' GLY . 28.4 m-85 -90.05 162.42 35.25 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.813 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -71.15 70.11 2.38 Favored 'Trans proline' 0 C--N 1.346 0.406 0 C-N-CA 122.468 2.112 . . . . 0.0 112.229 -179.881 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 19.8 tt . . . . . 0 C--N 1.328 -0.35 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.07 179.895 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.518 0.226 0 N-CA-C 112.597 -0.201 . . . . 0.0 112.597 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.59 HD13 HG13 ' A' ' 4' ' ' ILE . 0.2 OUTLIER -136.7 137.62 24.13 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 120.596 0.236 . . . . 0.0 110.599 179.991 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_exo -46.17 -28.42 5.5 Favored 'Trans proline' 0 C--N 1.347 0.476 0 C-N-CA 122.672 2.248 . . . . 0.0 112.752 -179.728 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.59 HG13 HD13 ' A' ' 2' ' ' LEU . 5.1 pt -80.07 153.39 4.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.03 179.892 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.453 ' HA2' ' CD2' ' A' ' 16' ' ' PHE . . . 138.16 -123.76 2.76 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.697 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 65.4 t-105 -127.02 -45.65 1.56 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.723 0.297 . . . . 0.0 111.281 -179.708 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 0.4 OUTLIER -146.84 179.94 7.23 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.157 0.504 . . . . 0.0 111.102 -179.52 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.589 ' HA ' ' CD1' ' A' ' 14' ' ' TRP . 1.5 mp -58.23 158.73 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.655 -0.702 . . . . 0.0 111.454 -179.873 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.462 ' N ' HG22 ' A' ' 8' ' ' ILE . 3.9 tt0 -101.2 175.95 5.41 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.718 -179.884 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.433 ' N ' ' CD ' ' A' ' 11' ' ' PRO . 9.6 ttp180 -89.56 -49.13 0.39 Allowed Pre-proline 0 C--N 1.326 -0.415 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.343 -179.738 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.433 ' CD ' ' N ' ' A' ' 10' ' ' ARG . 90.6 Cg_endo -81.08 -37.48 0.31 Allowed 'Trans proline' 0 C--N 1.347 0.47 0 C-N-CA 122.273 1.982 . . . . 0.0 112.536 -179.803 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER 176.45 149.76 0.13 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.036 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 72.02 -145.59 38.29 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.671 179.666 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.589 ' CD1' ' HA ' ' A' ' 8' ' ' ILE . 12.1 m0 -117.97 179.88 3.96 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.582 0.23 . . . . 0.0 110.49 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . 0.401 ' CD1' ' C ' ' A' ' 15' ' ' TYR . 0.0 OUTLIER -132.32 162.73 30.3 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.854 0.359 . . . . 0.0 111.203 179.987 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' PHE . . . . . 0.48 ' CE2' HD12 ' A' ' 4' ' ' ILE . 1.2 m-85 -90.4 146.05 33.76 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.934 -179.881 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 85.3 Cg_endo -78.51 -172.48 1.52 Allowed 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.66 2.24 . . . . 0.0 112.322 179.92 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 8.9 tp . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.11 179.962 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.545 ' C ' HD23 ' A' ' 2' ' ' LEU . . . . . . . . 0 N--CA 1.452 -0.295 0 N-CA-C 112.523 -0.231 . . . . 0.0 112.523 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.655 ' N ' HD23 ' A' ' 2' ' ' LEU . 0.1 OUTLIER -137.4 125.75 14.59 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 120.457 0.17 . . . . 0.0 110.833 179.966 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 80.2 Cg_exo -44.88 -29.66 3.83 Favored 'Trans proline' 0 C--N 1.348 0.531 0 C-N-CA 122.697 2.265 . . . . 0.0 112.73 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.4 pt -80.63 150.28 4.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.874 179.796 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 141.49 -117.22 1.18 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.498 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 60.1 t-105 -133.29 -44.94 0.84 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.68 0.276 . . . . 0.0 111.419 -179.813 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.66 ' CD2' HD12 ' A' ' 8' ' ' ILE . 0.3 OUTLIER -147.2 179.23 7.78 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 121.054 0.454 . . . . 0.0 111.189 -179.485 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.66 HD12 ' CD2' ' A' ' 7' ' ' TRP . 2.8 mp -57.69 158.86 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 115.848 -0.614 . . . . 0.0 111.467 -179.878 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.472 ' N ' HG22 ' A' ' 8' ' ' ILE . 4.2 tt0 -99.04 179.07 4.74 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.856 -179.882 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.452 ' N ' ' CD ' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -89.33 -47.97 0.41 Allowed Pre-proline 0 C--N 1.326 -0.456 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.456 -179.871 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.452 ' CD ' ' N ' ' A' ' 10' ' ' ARG . 93.2 Cg_endo -82.6 -43.7 0.08 OUTLIER 'Trans proline' 0 C--N 1.347 0.498 0 C-N-CA 122.348 2.032 . . . . 0.0 112.407 -179.808 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.1 p 179.59 142.06 0.13 Allowed 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.848 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 85.49 -143.25 19.98 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.523 179.941 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.606 ' CD1' ' HA ' ' A' ' 8' ' ' ILE . 7.9 m0 -121.87 179.06 4.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.588 0.232 . . . . 0.0 110.672 179.954 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . 0.407 ' HB3' ' HG3' ' A' ' 9' ' ' GLU . 0.1 OUTLIER -138.82 -178.22 5.22 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-O 120.878 0.37 . . . . 0.0 110.788 179.919 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' PHE . . . . . . . . . . . . . 3.7 m-85 -104.97 160.87 24.5 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.092 -179.838 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -75.83 -165.28 0.29 Allowed 'Trans proline' 0 C--N 1.345 0.357 0 C-N-CA 122.78 2.32 . . . . 0.0 112.273 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.5 mp . . . . . 0 C--N 1.33 -0.247 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.95 179.986 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.371 0 N-CA-C 112.524 -0.23 . . . . 0.0 112.524 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 15.1 mt -145.68 137.92 13.47 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 120.481 0.181 . . . . 0.0 110.87 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_exo -48.35 -27.4 9.87 Favored 'Trans proline' 0 C--N 1.346 0.442 0 C-N-CA 122.484 2.122 . . . . 0.0 112.492 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.734 HD12 ' HZ ' ' A' ' 16' ' ' PHE . 3.8 pt -86.86 152.56 3.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.907 179.856 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 143.66 -116.57 0.99 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.421 -179.86 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 61.9 t-105 -133.82 -47.16 0.8 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.709 0.29 . . . . 0.0 111.039 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 9.6 t-105 -149.93 176.39 10.8 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.914 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.558 ' HA ' ' CD1' ' A' ' 14' ' ' TRP . 4.1 mm -48.14 159.22 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.638 -179.901 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.422 ' HG3' ' HB3' ' A' ' 15' ' ' TYR . 3.0 tt0 -105.33 178.17 4.64 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.707 179.909 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.416 ' N ' ' CD ' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -89.41 -51.24 0.37 Allowed Pre-proline 0 C--N 1.326 -0.438 0 CA-C-N 115.975 -0.557 . . . . 0.0 111.187 -179.779 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.416 ' CD ' ' N ' ' A' ' 10' ' ' ARG . 72.0 Cg_endo -81.33 -48.5 0.06 OUTLIER 'Trans proline' 0 C--N 1.346 0.44 0 C-N-CA 122.293 1.995 . . . . 0.0 112.439 -179.892 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 67.6 m -166.57 157.08 12.19 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.957 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 59.51 -149.82 39.16 Favored Glycine 0 N--CA 1.452 -0.248 0 C-N-CA 120.862 -0.685 . . . . 0.0 112.648 179.764 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.558 ' CD1' ' HA ' ' A' ' 8' ' ' ILE . 30.2 m0 -109.92 179.4 4.12 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.591 0.234 . . . . 0.0 110.601 -179.861 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . 0.422 ' HB3' ' HG3' ' A' ' 9' ' ' GLU . 1.1 p90 -131.98 167.18 20.11 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.828 0.347 . . . . 0.0 110.984 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' PHE . . . . . 0.734 ' HZ ' HD12 ' A' ' 4' ' ' ILE . 10.5 m-85 -102.78 163.08 18.3 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.913 -179.963 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo -67.48 88.69 0.34 Allowed 'Trans proline' 0 C--N 1.346 0.409 0 C-N-CA 122.638 2.225 . . . . 0.0 112.327 179.893 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.9 mm . . . . . 0 C--N 1.327 -0.38 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.191 179.842 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.4 0 N-CA-C 112.478 -0.249 . . . . 0.0 112.478 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.3 mt -139.18 144.88 42.42 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 120.631 0.253 . . . . 0.0 110.831 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_exo -50.34 -24.93 12.71 Favored 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.575 2.184 . . . . 0.0 112.447 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.9 pt -79.8 154.39 4.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.055 179.855 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 134.88 -121.65 2.67 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.455 -179.863 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 36.0 t-105 -134.68 -44.19 0.75 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.685 0.278 . . . . 0.0 111.351 -179.84 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 0.5 OUTLIER -147.4 -179.32 6.77 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 121.095 0.474 . . . . 0.0 111.09 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.62 ' HA ' ' CD1' ' A' ' 14' ' ' TRP . 13.5 mt -53.75 158.53 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 115.688 -0.687 . . . . 0.0 111.718 -179.69 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.504 ' N ' HG22 ' A' ' 8' ' ' ILE . 3.6 tt0 -105.52 177.49 4.84 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.789 -0.642 . . . . 0.0 110.866 -179.703 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.448 ' N ' ' CD ' ' A' ' 11' ' ' PRO . 12.3 tpp180 -89.61 -46.59 0.41 Allowed Pre-proline 0 C--N 1.327 -0.389 0 CA-C-N 115.797 -0.638 . . . . 0.0 111.932 -179.574 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.448 ' CD ' ' N ' ' A' ' 10' ' ' ARG . 71.8 Cg_endo -80.69 -48.09 0.07 OUTLIER 'Trans proline' 0 C--N 1.349 0.582 0 C-N-CA 122.209 1.939 . . . . 0.0 112.804 -179.475 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 4.3 p -179.3 129.04 0.1 Allowed 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.93 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 96.52 -141.33 15.54 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.455 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.62 ' CD1' ' HA ' ' A' ' 8' ' ' ILE . 10.0 m0 -120.48 174.78 6.34 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.736 0.303 . . . . 0.0 110.778 179.92 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . 0.419 ' CE1' HG22 ' A' ' 18' ' ' ILE . 0.1 OUTLIER -132.38 177.73 7.37 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.383 -0.372 . . . . 0.0 110.596 179.951 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' PHE . . . . . 0.401 ' O ' ' CE1' ' A' ' 15' ' ' TYR . 26.1 m-85 -89.77 160.9 40.25 Favored Pre-proline 0 C--N 1.328 -0.365 0 CA-C-N 116.418 -0.355 . . . . 0.0 111.025 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 68.2 Cg_endo -74.49 76.24 3.23 Favored 'Trans proline' 0 C--N 1.343 0.286 0 C-N-CA 122.722 2.281 . . . . 0.0 112.238 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.419 HG22 ' CE1' ' A' ' 15' ' ' TYR . 7.5 tp . . . . . 0 C--N 1.33 -0.281 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.076 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.388 0 N-CA-C 112.793 -0.123 . . . . 0.0 112.793 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 15.0 mt -140.6 142.63 29.55 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-O 120.507 0.194 . . . . 0.0 110.858 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 81.2 Cg_exo -48.02 -27.94 9.71 Favored 'Trans proline' 0 C--N 1.346 0.404 0 C-N-CA 122.655 2.237 . . . . 0.0 112.53 -179.834 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 8.2 pt -83.39 160.23 3.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.8 179.804 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 133.39 -121.62 2.88 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.653 -0.785 . . . . 0.0 112.687 -179.911 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 70.9 t-105 -128.41 -49.45 1.29 Allowed 'General case' 0 C--N 1.331 -0.203 0 N-CA-C 111.599 0.222 . . . . 0.0 111.599 -179.697 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.666 ' CD1' HD12 ' A' ' 8' ' ' ILE . 1.6 t-105 -148.87 175.1 11.55 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.898 0.38 . . . . 0.0 111.199 -179.447 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.666 HD12 ' CD1' ' A' ' 7' ' ' TRP . 2.2 mp -48.77 155.46 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.622 -179.738 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.49 ' HG3' ' HB3' ' A' ' 15' ' ' TYR . 2.8 tt0 -100.69 177.93 4.85 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.896 -0.593 . . . . 0.0 111.136 -179.681 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.431 ' N ' ' CD ' ' A' ' 11' ' ' PRO . 1.9 tpt180 -89.43 -50.03 0.38 Allowed Pre-proline 0 C--N 1.326 -0.423 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.212 179.961 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.431 ' CD ' ' N ' ' A' ' 10' ' ' ARG . 89.9 Cg_endo -82.89 -39.67 0.13 Allowed 'Trans proline' 0 C--N 1.348 0.512 0 C-N-CA 122.491 2.127 . . . . 0.0 112.544 -179.804 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 17.9 p -177.52 157.77 1.31 Allowed 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.056 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 59.82 -148.5 42.23 Favored Glycine 0 N--CA 1.453 -0.215 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.517 179.909 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.598 ' CD1' ' HA ' ' A' ' 8' ' ' ILE . 30.5 m0 -115.54 174.96 5.74 Favored 'General case' 0 C--N 1.332 -0.186 0 C-N-CA 122.183 0.193 . . . . 0.0 110.513 179.96 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . 0.496 ' CD2' ' O ' ' A' ' 8' ' ' ILE . 3.3 p90 -122.08 166.6 14.28 Favored 'General case' 0 N--CA 1.462 0.172 0 CA-C-O 120.794 0.33 . . . . 0.0 110.688 179.151 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' PHE . . . . . . . . . . . . . 1.8 m-85 -91.19 148.02 36.88 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.899 179.843 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -72.65 71.42 3.25 Favored 'Trans proline' 0 C--N 1.345 0.363 0 C-N-CA 122.563 2.175 . . . . 0.0 112.487 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 40.9 mt . . . . . 0 C--N 1.328 -0.353 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.049 -179.903 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.333 0 N-CA-C 112.425 -0.27 . . . . 0.0 112.425 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.424 ' O ' ' HB2' ' A' ' 14' ' ' TRP . 0.3 OUTLIER -128.48 145.35 55.58 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 120.522 0.201 . . . . 0.0 110.614 179.929 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 82.0 Cg_exo -44.37 -28.37 2.5 Favored 'Trans proline' 0 C--N 1.347 0.467 0 C-N-CA 122.705 2.27 . . . . 0.0 112.755 -179.848 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.703 HD12 ' CZ ' ' A' ' 16' ' ' PHE . 3.4 pt -79.84 151.85 4.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.765 179.725 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.413 ' HA2' ' CZ ' ' A' ' 16' ' ' PHE . . . 133.81 -120.5 2.53 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.578 -179.948 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 24.2 t-105 -121.74 -64.61 1.2 Allowed 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 120.642 0.258 . . . . 0.0 111.31 -179.75 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.741 ' CD2' HD12 ' A' ' 8' ' ' ILE . 0.0 OUTLIER -140.7 177.19 8.2 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.846 0.355 . . . . 0.0 111.154 -179.582 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.741 HD12 ' CD2' ' A' ' 7' ' ' TRP . 2.5 mp -46.19 155.53 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.435 -179.77 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.433 ' N ' HG22 ' A' ' 8' ' ' ILE . 3.3 tt0 -102.81 179.82 4.17 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.091 -179.534 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.439 ' N ' ' CD ' ' A' ' 11' ' ' PRO . 7.7 mtt-85 -89.36 -48.41 0.4 Allowed Pre-proline 0 C--N 1.325 -0.493 0 CA-C-N 115.581 -0.736 . . . . 0.0 111.149 179.908 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.439 ' CD ' ' N ' ' A' ' 10' ' ' ARG . 93.1 Cg_endo -82.25 -40.93 0.13 Allowed 'Trans proline' 0 C--N 1.346 0.446 0 C-N-CA 122.352 2.035 . . . . 0.0 112.424 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.2 p 175.87 144.54 0.07 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.992 179.912 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 81.11 -142.89 23.57 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.708 179.812 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.622 ' CD1' ' HA ' ' A' ' 8' ' ' ILE . 13.4 m0 -123.07 168.7 12.03 Favored 'General case' 0 CA--C 1.53 0.207 0 N-CA-C 110.276 -0.268 . . . . 0.0 110.276 179.91 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . 0.442 ' CD2' ' O ' ' A' ' 8' ' ' ILE . 4.1 p90 -114.95 177.58 4.6 Favored 'General case' 0 N--CA 1.463 0.218 0 CA-C-O 120.845 0.355 . . . . 0.0 110.885 179.442 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' PHE . . . . . 0.703 ' CZ ' HD12 ' A' ' 4' ' ' ILE . 5.4 m-85 -119.83 152.78 54.25 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.743 179.901 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -75.81 58.95 5.57 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.573 2.182 . . . . 0.0 112.353 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 5.6 tp . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.054 -179.915 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.318 0 N-CA-C 112.417 -0.273 . . . . 0.0 112.417 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.452 ' N ' HD12 ' A' ' 2' ' ' LEU . 0.0 OUTLIER -130.71 142.26 44.9 Favored Pre-proline 0 C--N 1.329 -0.298 0 N-CA-C 110.521 -0.177 . . . . 0.0 110.521 179.877 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.553 ' O ' HG23 ' A' ' 4' ' ' ILE . 16.6 Cg_exo -67.42 59.58 0.72 Allowed 'Trans proline' 0 C--N 1.347 0.484 0 C-N-CA 122.664 2.243 . . . . 0.0 112.517 -179.858 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.553 HG23 ' O ' ' A' ' 3' ' ' PRO . 12.2 pt -160.09 167.28 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.727 179.876 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.432 ' HA2' ' CD1' ' A' ' 16' ' ' PHE . . . 116.64 -99.22 0.84 Allowed Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.588 -0.815 . . . . 0.0 112.591 179.897 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 48.9 t-105 -149.39 -39.31 0.15 Allowed 'General case' 0 C--N 1.33 -0.246 0 N-CA-C 111.779 0.289 . . . . 0.0 111.779 -179.714 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.486 ' CD1' HD12 ' A' ' 8' ' ' ILE . 1.4 t-105 -145.13 178.81 7.79 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 121.184 0.516 . . . . 0.0 111.422 -179.437 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.576 ' HA ' ' CD1' ' A' ' 14' ' ' TRP . 1.5 mt -62.49 158.5 3.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.512 -0.767 . . . . 0.0 111.36 -179.829 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.448 ' N ' HG22 ' A' ' 8' ' ' ILE . 4.3 tt0 -95.9 176.46 6.11 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.916 -0.583 . . . . 0.0 110.849 179.887 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.473 ' N ' ' CD ' ' A' ' 11' ' ' PRO . 10.3 ttt180 -89.43 -45.47 0.42 Allowed Pre-proline 0 C--N 1.326 -0.416 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.567 -179.86 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.473 ' CD ' ' N ' ' A' ' 10' ' ' ARG . 92.1 Cg_endo -82.5 -44.13 0.08 OUTLIER 'Trans proline' 0 C--N 1.349 0.572 0 C-N-CA 122.129 1.886 . . . . 0.0 112.388 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 21.4 p 177.17 133.37 0.06 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.853 179.894 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 97.13 -142.2 16.04 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.675 179.868 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.576 ' CD1' ' HA ' ' A' ' 8' ' ' ILE . 5.8 m0 -125.74 -177.71 4.01 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.608 0.242 . . . . 0.0 110.644 -179.965 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . 0.416 ' HB3' ' HG3' ' A' ' 9' ' ' GLU . 0.1 OUTLIER -147.96 170.96 16.58 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 120.807 0.337 . . . . 0.0 111.106 179.93 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' PHE . . . . . 0.432 ' CD1' ' HA2' ' A' ' 5' ' ' GLY . 29.3 m-85 -96.64 161.63 25.99 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.877 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -73.25 154.22 51.44 Favored 'Trans proline' 0 C--N 1.344 0.317 0 C-N-CA 122.536 2.157 . . . . 0.0 112.282 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 29.8 mm . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.13 179.968 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.418 0 N-CA-C 112.658 -0.177 . . . . 0.0 112.658 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.436 ' O ' ' HB2' ' A' ' 14' ' ' TRP . 0.5 OUTLIER -125.43 130.65 24.05 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 120.397 0.141 . . . . 0.0 110.648 179.878 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 99.6 Cg_exo -42.03 -31.24 1.48 Allowed 'Trans proline' 0 C--N 1.348 0.532 0 C-N-CA 122.785 2.323 . . . . 0.0 112.854 -179.826 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.423 HD12 ' CZ ' ' A' ' 16' ' ' PHE . 3.5 pt -83.29 149.64 4.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.86 179.754 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 141.72 -111.16 0.68 Allowed Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.544 -0.836 . . . . 0.0 112.581 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 73.5 t-105 -133.4 -59.32 0.87 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.507 0.194 . . . . 0.0 111.512 -179.617 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 0.8 OUTLIER -135.62 179.05 6.57 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 121.051 0.453 . . . . 0.0 111.489 -179.359 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.542 ' HA ' ' CD1' ' A' ' 14' ' ' TRP . 6.0 mt -65.64 153.64 8.17 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 115.753 -0.658 . . . . 0.0 111.332 -179.848 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -93.44 179.97 5.23 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.692 -0.685 . . . . 0.0 111.115 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.427 ' N ' ' HD2' ' A' ' 11' ' ' PRO . 3.3 ttt180 -89.44 -52.29 0.35 Allowed Pre-proline 0 C--N 1.325 -0.463 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.2 -179.786 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.427 ' HD2' ' N ' ' A' ' 10' ' ' ARG . 72.8 Cg_endo -78.04 -41.27 0.31 Allowed 'Trans proline' 0 C--N 1.347 0.46 0 C-N-CA 122.339 2.026 . . . . 0.0 112.465 -179.905 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER 175.69 145.73 0.08 Allowed 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.1 179.872 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 83.89 -152.26 28.4 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.857 179.803 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.542 ' CD1' ' HA ' ' A' ' 8' ' ' ILE . 9.1 m0 -123.53 173.53 7.98 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 110.407 -0.22 . . . . 0.0 110.407 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . 0.436 ' CD2' ' O ' ' A' ' 8' ' ' ILE . 6.6 p90 -125.71 164.71 20.05 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.698 0.285 . . . . 0.0 110.698 179.691 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' PHE . . . . . 0.423 ' CZ ' HD12 ' A' ' 4' ' ' ILE . 11.4 m-85 -90.05 151.55 45.16 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.853 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.785 ' C ' HD12 ' A' ' 18' ' ' ILE . 73.2 Cg_endo -77.74 160.71 31.03 Favored 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.691 2.261 . . . . 0.0 112.607 -179.898 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.785 HD12 ' C ' ' A' ' 17' ' ' PRO . 2.7 mp . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.743 179.772 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.434 ' N ' ' O ' ' A' ' 14' ' ' TRP . . . . . . . . 0 N--CA 1.452 -0.249 0 N-CA-C 112.592 -0.203 . . . . 0.0 112.592 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.897 HD12 HG13 ' A' ' 4' ' ' ILE . 0.0 OUTLIER -134.58 130.85 20.04 Favored Pre-proline 0 C--N 1.331 -0.211 0 CA-C-O 120.458 0.17 . . . . 0.0 110.572 -179.93 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 92.0 Cg_exo -42.45 -29.19 1.18 Allowed 'Trans proline' 0 C--N 1.347 0.496 0 C-N-CA 122.905 2.403 . . . . 0.0 113.209 -179.555 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.897 HG13 HD12 ' A' ' 2' ' ' LEU . 4.1 pt -79.85 150.49 4.96 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 116.531 -0.304 . . . . 0.0 110.772 179.843 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.459 ' HA2' ' CE2' ' A' ' 16' ' ' PHE . . . 141.01 -132.47 5.39 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.538 -179.713 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . 0.419 ' HB2' ' HD3' ' A' ' 17' ' ' PRO . 35.0 t-105 -119.29 -39.66 2.88 Favored 'General case' 0 C--N 1.332 -0.194 0 N-CA-C 111.673 0.249 . . . . 0.0 111.673 -179.633 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 2.4 t-105 -150.15 175.54 11.65 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.956 0.408 . . . . 0.0 111.101 -179.611 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.566 ' HA ' ' CD1' ' A' ' 14' ' ' TRP . 2.7 mp -58.06 159.12 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.389 -179.865 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.474 ' N ' HG22 ' A' ' 8' ' ' ILE . 3.9 tt0 -101.34 176.38 5.26 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.728 -179.892 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.436 ' N ' ' CD ' ' A' ' 11' ' ' PRO . 2.3 tpt180 -89.59 -48.43 0.4 Allowed Pre-proline 0 C--N 1.327 -0.392 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.36 -179.782 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.436 ' CD ' ' N ' ' A' ' 10' ' ' ARG . 72.7 Cg_endo -80.15 -51.2 0.05 OUTLIER 'Trans proline' 0 C--N 1.347 0.5 0 C-N-CA 122.154 1.903 . . . . 0.0 112.523 -179.862 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -169.75 140.79 2.18 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.048 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 80.49 -145.85 26.84 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.931 -0.652 . . . . 0.0 112.724 179.718 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.566 ' CD1' ' HA ' ' A' ' 8' ' ' ILE . 15.2 m0 -115.6 -179.26 3.59 Favored 'General case' 0 C--N 1.331 -0.231 0 N-CA-C 110.421 -0.214 . . . . 0.0 110.421 -179.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . 0.408 ' C ' ' CD2' ' A' ' 15' ' ' TYR . 0.1 OUTLIER -129.81 173.96 10.17 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.986 0.422 . . . . 0.0 111.531 -179.679 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' PHE . . . . . 0.459 ' CE2' ' HA2' ' A' ' 5' ' ' GLY . 0.8 OUTLIER -122.41 137.17 27.3 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.843 -179.971 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.49 ' O ' HD13 ' A' ' 18' ' ' ILE . 96.4 Cg_endo -80.34 150.65 19.88 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.579 2.186 . . . . 0.0 112.339 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.49 HD13 ' O ' ' A' ' 17' ' ' PRO . 26.1 mm . . . . . 0 C--N 1.33 -0.248 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.026 179.93 . . . . . . . . 1 1 . 1 stop_ save_